0001571049-16-017008.txt : 20160802 0001571049-16-017008.hdr.sgml : 20160802 20160802161707 ACCESSION NUMBER: 0001571049-16-017008 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160802 DATE AS OF CHANGE: 20160802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Semler Scientific, Inc. CENTRAL INDEX KEY: 0001554859 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 261367393 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36305 FILM NUMBER: 161800694 BUSINESS ADDRESS: STREET 1: 2330 N.W. EVERETT STREET CITY: PORTLAND STATE: OR ZIP: 97210 BUSINESS PHONE: 408-627-4557 MAIL ADDRESS: STREET 1: 2330 N.W. EVERETT STREET CITY: PORTLAND STATE: OR ZIP: 97210 10-Q 1 t1601863_10q.htm FORM 10-Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 10-Q

  

 

 

þ   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended June 30, 2016

 

OR

 

¨   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period from ___ to ___

 

Commission File Number 001-36305

 

 

 

SEMLER SCIENTIFIC, INC.

(Exact name of Registrant as specified in its Charter)

  

 

 

Delaware 26-1367393
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
   
2330 N.W. Everett  
Portland, Oregon 97210
(Address of principal executive offices) (Zip Code)

 

Registrant's Telephone Number, Including Area Code: (877) 774-4211

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ  No ¨   

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  þ  No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer ¨   Accelerated Filer ¨
         
Non-Accelerated Filer ¨   Smaller Reporting Company x
(Do not check if a smaller reporting company)        

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

As of July 29, 2016, there were 5,123,568 shares of the issuer’s common stock, $0.001 par value per share, outstanding.

 

 

 

 

 

TABLE OF CONTENTS

 

        Page  
Part I.   Financial Information     1  
             
Item 1.   Financial Statements     1  
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations     11  
Item 3.   Quantitative and Qualitative Disclosures about Market Risk     16  
Item 4.   Controls and Procedures     16  
             
Part II.   Other Information     17  
             
Item 1.   Legal Proceedings     17  
Item 1A.   Risk Factors     17  
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds     17  
Item 3.   Defaults upon Senior Securities     17  
Item 4.   Mine Safety Disclosures     17  
Item 5.   Other Information     17  
Item 6.   Exhibits     17  
             
Signatures         18  

 

 i 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This quarterly report on Form 10-Q contains forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.

 

In some cases, you can identify forward-looking statements by terminology, such as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “believes,” “seeks,” “may,” “should,” “continue,” “could” or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this report.

 

You should read this quarterly report and the documents that we reference herein and therein and have filed as exhibits to this report, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this quarterly report is accurate as of the date of this report only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. These risks and uncertainties, along with others, are described above under the heading “Risk Factors” in our annual report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 26, 2016. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this quarterly report, and particularly our forward-looking statements, by these cautionary statements.

 

 ii 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Semler Scientific, Inc.

Condensed Statements of Operations

(In thousands, except share and per share amounts)

  

   (Unaudited)   (Unaudited) 
         
   For the three months ended
June 30		   For the six months ended
June 30		 
   2016   2015   2016   2015 
                 
Revenue  $1,636   $1,303   $3,136   $2,505 
                     
Operating expenses:                    
Cost of revenue   533    261    950    502 
Engineering and product development   182    406    452    715 
Sales and marketing   1,028    1,288    2,001    2,495 
General and administrative   763    665    1,534    1,460 
Total operating expenses   2,506    2,620    4,937    5,172 
                     
Loss from operations   (870)   (1,317)   (1,801)   (2,667)
                     
Other expense:   (96)   (24)   (171)   (46)
                     
Net loss  $(966)  $(1,341)  $(1,972)  $(2,713)
                     
Net loss per share, basic and diluted  $(0.19)  $(0.27)  $(0.38)  $(0.56)
                     
Weighted average number of shares used in computing basic and diluted loss per share   5,123,568    4,978,878    5,123,568    4,871,614 

 

See accompanying notes to unaudited condensed financial statements.

 

 1 

 

Semler Scientific, Inc.

Condensed Balance Sheets

(In thousands, except share and per share amounts)

 

  

(Unaudited)

June 30,

   December 31, 
   2016   2015 
         
Assets          
           
Current Assets:          
Cash  $1,022   $405 
Trade accounts receivable, net of allowance for doubtful accounts of $94 and $183, respectively   607    1,278 
Prepaid expenses and other current assets   126    69 
Total current assets   1,755    1,752 
           
Assets for lease, net   839    830 
Property and equipment, net   452    497 
Long-term deposits   15    - 
Total assets  $3,061   $3,079 
           
Liabilities and Stockholders' Deficit          
           
Current liabilities:          
Accounts payable  $430   $839 
Accrued expenses   2,183    2,317 
Deferred revenue   667    952 
Total current liabilities   3,280    4,108 
           
Long-term liabilities:          
           
Deferred rent   43    43 
Accrued interest expense   85    - 
Related party loan payable net of debt discount of $199 and $0, respectively   1,301    - 
Loan payable net of debt discount of $95 and $0, respectively   883    - 
           
Total long-term liabilities   2,312    43 
           
Stockholders' deficit:          
Common stock, $0.001 par value; 50,000,000 shares authorized; 5,148,568 and 5,148,568 shares issued, and 5,123,568 and 5,123,568 outstanding (net of treasury shares of 25,000 and 25,000), respectively   5    5 
Additional paid-in capital   21,804    21,291 
Accumulated deficit   (24,340)   (22,368)
           
Total stockholders' deficit   (2,531)   (1,072)
           
Total liabilities and stockholders' deficit  $3,061   $3,079 

 

See accompanying notes to unaudited condensed financial statements.

 

 2 

  

Semler Scientific, Inc.

Condensed Statements of Cash Flows

(In thousands) 

 

  

(Unaudited)

Six months ended June 30

 
   2016   2015 
     
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(1,972)  $(2,713)
           
Reconciliation of Net Loss to Net Cash Used in Operating Activities:          
Amortization of debt discount   84    37 
Depreciation   221    129 
Loss on disposal of assets for lease   136    44 
Allowance for doubtful accounts   18    73 
Stock-based compensation expense   135    63 
Changes in Operating Assets and Liabilities:          
Trade accounts receivable   653    20 
Prepaid expenses and other current assets   (72)   9 
Accounts payable   (409)   27 
Accrued expenses   (49)   21 
Deferred revenue   (285)   (132)
Net Cash Used in Operating Activities   (1,540)   (2,422)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Additions to property and equipment   (15)   (45)
Purchase of assets for lease   (306)   (261)
Net Cash Used in Investing Activities   (321)   (306)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Issuance of common stock   -    999 
Stock options exercised   -    13 
Offering costs   -    (100)
Proceeds from loans payable   2,478    - 
Net Cash Provided by Financing Activities   2,478    912 
           
INCREASE (DECREASE) IN CASH   617    (1,816)
CASH, BEGINNING OF PERIOD   405    4,156 
           
CASH, END OF PERIOD  $1,022   $2,340 
Cash paid for interest  $-   $13 
Supplemental disclosure of noncash financing activity:          
Fair value of warrants issued to lenders  $363   $- 

 

See accompanying notes to unaudited condensed financial statements

 

 3 

 

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

  

1. Basis of Presentation

 

Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K filed with the SEC on February 26, 2016 (the “Annual Report”). The balance sheet as of December 31, 2015 included in this report has been derived from the audited financial statements included in the Annual Report. In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year. Items in prior period financial statements have been adjusted to conform with the current period presentation.

 

2. Going Concern

 

The Company has incurred recurring losses since inception and expects to continue to incur losses as a result of costs and expenses related to the Company’s marketing and other promotional activities, research and continued development of its product. As of June 30, 2016, the Company has negative working capital of $1,525, cash of $1,022 and stockholders’ deficit of $2,531. The Company’s principal sources of cash have included the issuance of equity securities, borrowings under loan agreements, revenue from leasing its product and providing testing services. To increase revenue, the Company’s operating expenses will continue to grow and, as a result, the Company will need to generate significant additional revenue to achieve profitability.

 

The Company’s financial statements as of and for the three and six months ended June 30, 2016 have been prepared under the assumption that the Company will continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate additional revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company can give no assurances that additional capital that the Company is able to obtain, if any, will be sufficient to meet the Company’s needs. If the Company is unable to raise additional capital or increase revenue from leasing its product and providing testing services within the next twelve months to continue to fund operations at its current cash expenditure levels, the Company’s operations will need to be curtailed. The foregoing conditions raise substantial doubt about the Company’s ability to continue as a going concern.

 

3. Assets for Lease, net

 

Assets for lease consist of the following:

 

   June 30,
2016		   December 31,
2015		 
         
Assets for lease  $1,333   $1,280 
Less: Accumulated Depreciation   (494)   (450)
Assets for lease, net  $839   $830 

 

Depreciation expense amounted to $81 and $66 for the three months ended June 30, 2016 and June 30, 2015, respectively. Depreciation expense amounted to $161 and $123 for the six months ended June 30, 2016 and June 30, 2015, respectively. Reduction to accumulated depreciation for returned items was $88 and $27 for the three months ended June 30, 2016 and June 30, 2015, respectively. Reduction to accumulated depreciation for returned items was $117 and $41 for the six months ended June 30, 2016 and June 30, 2015, respectively.

 

 4 

 

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

 

4. Property and Equipment, net

 

Property and equipment, net consists of the following:

 

   June 30,
2016		   December 31,
2015		 
         
Property and equipment  $557   $542 
Less: accumulated depreciation   (105)   (45)
Property and equipment, net  $452   $497 

 

Depreciation expense amounted to $30 and $4 for the three months ended June 30, 2016 and 2015, respectively. Depreciation expense amounted to $60 and $6 for the six months ended June 30, 2016 and 2015, respectively.

 

5. Accrued Expenses

 

Accrued expenses consist of the following:

 

   June 30,
2016		   December 31,
2015		 
         
Offering Costs  $227   $227 
Compensation   1,436    1,093 
Miscellaneous Accruals   520    997 
Total Accrued Expenses  $2,183   $2,317 

 

The accumulated offering costs that were accrued pertain to consulting fees associated with securing equity financing for the Company prior to the initial public offering. Prior to becoming Chief Executive Officer (“CEO”), the Company’s current CEO performed consulting services for the Company, which included managing finance, sales, marketing, operational and strategic planning for the Company, as well as assistance and strategic guidance in securing financing. The Company has agreed to a payment date of December 31, 2016 for these fees.

 

6. Commitments and Contingencies

 

Facilities Leases

 

Facilities lease expense recognized by the Company was $22 and $65 for the three months ended June 30, 2016 and 2015, respectively. Facilities lease expense recognized by the Company was $37 and $101 for the six months ended June 30, 2016 and 2015, respectively.

 

On September 23, 2014, the Company entered into a 36-month lease agreement for office space for the sales and marketing team located in Menlo Park, CA. The lease term commenced February 1, 2015 and is effective through January 31, 2018. Payments required under the terms of the lease are $17.0 per month from February 2015 to January 2016, $17.5 per month from February 2016 to January 2017, and $18.0 per month from February 2017 to January 2018. The Company anticipates total future lease payments of $104.8 for the year ended December 31, 2016; $215.4 for the year ended December 31, 2017; and $18.0 for the year ended December 31, 2018. On July 15, 2015, the Company entered into a 30-month sublease agreement for the Menlo Park office space, which commenced August 1, 2015 and is effective through the term of the lease, January 31, 2018. Payments required to the Company under the terms of the sublease are $15.5 per month from August 2015 to July 2016,

 

 5 

 

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

 

$16.0 per month from August 2016 to July 2017, and $16.5 per month from August 2017 to January 2018. The Company anticipates receipt of total future sublease payments of $95.5 for the year ended December 31, 2016; $194.4 for the year ended December 31, 2017; and $16.5 for the year ended December 31, 2018.

 

Loans Payable

 

Loans from Related Parties 

 

On January 15, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $1,000 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $1,000 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

On January 21, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $500 unsecured loan for a 24-month term at a fixed interest rate of 5% p.a. Under the loan agreement, the Company will pay $500 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

Other Loans

 

On March 31, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $700 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $700 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 79,459 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

On April 5, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $160 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $160 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 18,162 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

On May 20, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $80 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $80 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the

 

 6 

  

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

 

Company issued the accredited investor a two-year warrant to purchase 9,081 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

The Company uses the Black-Scholes pricing model to determine the relative fair market value of warrants. The relative fair market value of each warrant is estimated on the date of grant. The relative fair value of the warrants granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented:

 

   Three months ended
June 30,		   Six months ended June 30, 
   2016   2015   2016   2015 
Expected term (in years)   2    -    2    - 
Risk-free interest rate   0.73 – 0.89%   -    0.73 – 0.89 %   - 
Expected volatility   98.1 – 99.0 %   -    97.7 – 99.0 %   - 
Expected dividend rate.   0%   -    0%   - 

 

The assumptions are based on the following for each of the years presented:

 

Valuation Method — The Company estimates the relative fair value of warrants using the Black-Scholes pricing model.

 

Expected Term — The Company uses the amount of time the warrants are exercisable per the contractual terms of the award.

 

Volatility — Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the warrants.

 

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the warrants.

 

Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

 

For the three months ended June 30, 2016 and 2015 interest expense was $96 and $25, respectively. Of this total interest expense, the portion related to amortization of debt discount was $48 and $19, respectively. For the six months ended June 30, 2016 and 2015 interest expense was $170 and $49, respectively. Of this total interest expense, the portion related to amortization of debt discount was $84 and $37, respectively.

 

Indemnification Obligations

 

The Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company’s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company’s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment

 

 7 

 

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

 

under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.

 

7. Net Loss Per Common Share

 

Because the Company was in a loss position for each of the periods presented, diluted net loss per share is the same as basic net loss per share for each period as the inclusion of all potential common shares outstanding would have been anti-dilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive:

 

   Three months ended
June 30,		   Six months ended
June 30,		 
   2016   2015   2016   2015 
Weighted average shares outstanding:                    
Common stock warrants   706,331    359,714    645,353    359,714 
Options   2,069,911    736,722    2,027,480    727,069 
Total   2,776,242    1,096,436    2,672,833    1,086,783 

 

8. Stock Option Plan

 

The Company’s stock-based compensation program is designed to attract and retain employees while also aligning employees' interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (“2007 Plan”) or the stockholder-approved 2014 Stock Incentive Plan (“2014 Plan”). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the “Share Reserve”), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company’s Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. On January 1, 2015, the Share Reserve increased by 188,640 shares due to the automatic 4% increase. On January 1, 2016, the Share Reserve increased by 204,943 shares due to the automatic 4% increase. The Share Reserve is currently 2,343,583 shares for the year ending December 31, 2016.

 

In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of June 30, 2016, 0 shares of an aggregate total of 407,500 shares were available for future stock-based compensation grants under the 2007 Plan and 666,121 shares of an aggregate total of 2,343,583 shares were available for future stock-based compensation grants under the 2014 Plan.

 

Aggregate intrinsic value represents the difference between the closing market value as of June 30, 2016 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company’s stock option activity and related information for the six months ended June 30, 2016 is as follows:

 

 8 

 

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

 

   Options Outstanding 
   Number of
Stock Options
Outstanding		   Weighted
Average
Exercise Price		   Weighted
Average
Remaining
Contractual
Term (In Years)		   Aggregate
Intrinsic Value
 (in thousands)		 
Balance, January 1, 2016   1,909,911   $2.58    8.56   $813 
Options granted   160,000    2.23           
Options exercised   -    -           
Options forfeited/canceled   394    3.44           
Balance, June 30, 2016   2,069,517   $2.58    8.18   $280 
Exercisable as of June 30, 2016   1,581,140   $2.61    7.92   $280 

 

The total compensation cost related to unvested stock option awards not yet recognized was $802 as of June 30, 2016. The weighted average period over which the total unrecognized compensation cost related to these unvested stock awards will be recognized is 2.77 years. The estimated fair value of option shares vested during the quarters ended June 30, 2016 and 2015 was $66 and $31, respectively. The estimated fair value of option shares vested during the six months ended June 30, 2016 and 2015 was $135 and $63, respectively. The weighted average fair value of options granted during the quarter ended June 30, 2015 was $2.32 per share, or an aggregate grant date fair value of $116, respectively. There were no options granted during the quarter ended June 30, 2016. The weighted average fair value of options granted during the six months ended June 30, 2016 and 2015 was $1.43 per share and $1.75 per share, respectively, or an aggregate grant date fair value of $229 and $219, respectively.

 

On February 18, 2016 the Compensation Committee of the Company’s Board of Directors granted, and the full Board ratified, an option to acquire an aggregate of 125,000 shares under the 2014 Plan to the Company’s CEO. This option vests 25% on the one-year anniversary of the grant date and monthly thereafter for 36 months, such that the option is vested in full on the four-year anniversary of the grant date. On February 18, 2016 the Company’s Compensation Committee granted, and the full Board ratified, options to each of the then-seated non-employee Directors to acquire 5,000 shares, for an aggregate of 35,000 shares, under the 2014 Plan. These options vest on the one-year anniversary of their grant date.

 

Determining the Fair Value of Stock Options

 

The Company uses the Black-Scholes pricing model to determine the fair value of stock options. The fair value of each option grant is estimated on the date of the grant. The following assumptions for the periods presented were:

 

   Three months ended
June 30,		   Six months ended June 30, 
   2016   2015   2016   2015 
Expected term (in years)   -    5    5    5 
Risk-free interest rate   -    1.6%   1.21%   1.5 – 1.6%
Expected volatility   -    82.5%   80.4%   82.5 – 83.3%
Expected dividend rate.   -    0%   0%   0%

 

The assumptions are based on the following for each of the years presented:

 

Valuation Method — The Company estimates the fair value of its stock options using the Black-Scholes option pricing model.

 

Expected Term — The Company estimates the expected term consistent with the simplified method identified by the SEC. The Company elected to use the simplified method because of its limited history of stock option exercise activity and its stock options meet the criteria of the “plain-vanilla” options as defined by the SEC. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award.

 

 9 

 

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands, except share and per share amounts)

 

Volatility — Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the options.

 

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options.

 

Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

 

Forfeiture — The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of the awards, which are generally the vesting periods. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.

 

The Company has recorded an expense of $66 and $31 as it relates to stock-based compensation for the three months ended June 30, 2016 and 2015, respectively. The Company has recorded an expense of $135 and $63 as it relates to stock-based compensation for the six months ended June 30, 2016 and 2015, respectively, which was allocated as follows based on the role and responsibility of the recipient in the Company:

 

   Three months ended June 30,   Six months ended June 30 
   2016   2015   2016   2015 
Cost of Revenue  $1   $1   $1   $1 
Engineering and Product Development   5    5    18    7 
Sales and Marketing   17    10    42    25 
General and Administrative   43    15    74    30 
Total  $66   $31   $135   $63 

 

9. Subsequent Events

 

None.

 

 10 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis should be read together with our condensed unaudited financial statements and the related notes appearing elsewhere in this quarterly report on Form 10-Q and with the audited financial statements and notes for the fiscal year ended December 31, 2015, and the information under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed with the SEC on February 26, 2016, or the Annual Report. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under “Risk Factors” in our Annual Report.

 

Overview

 

 

We are an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare insurers and physician groups. Our mission is to develop, manufacture and market innovative proprietary products and services that assist our customers in evaluating and treating chronic diseases. In 2011, we began commercializing our first patented and U.S. Food and Drug Administration, or FDA, cleared product, which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease, or PAD, which is associated with higher risk of heart attacks and strokes. In March 2015, we received FDA 510(k) clearance for the next generation version of our product, QuantaFlo™, which we began commercializing in August 2015. In April 2015, we launched our multi-test service platform, WellChec™, to more comprehensively evaluate our customers’ patients for chronic disease, including heart attacks and strokes. We believe the combination of our proprietary test, QuantaFlo™, and our multi-test service platform, WellChec™, position us to provide valuable information to our insurance company and physician customers, which in turn permit them to better guide patient care.

 

In the three months ended June 30, 2016 we had total revenue of $1,636,000 and a net loss of $966,000 compared to total revenue of $1,303,000 and a net loss of $1,341,000 in the same period in 2015. In the six months ended June 30, 2016 we had total revenue of $3,136,000 and a net loss of $1,972,000 compared to total revenue of $2,505,000 and a net loss of $2,713,000 in the same period in 2015.

 

Emerging Growth Company Elections

 

The JOBS Act provides that an emerging growth company, such as our company, can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption. As a result, our financial statements may not be comparable to other public companies that comply with public company effective dates. In the future, we may elect to opt out of the extended period for adopting new accounting standards. If we do so, we would need to disclose such decision and it would be irrevocable.

 

Factors Affecting Future Results

 

We have not identified any factors that have a recurring effect that are necessary to understand period to period comparisons as appropriate, nor any one-time events that have an effect on the financials. We launched our WellChec™ testing services platform in 2015, which significantly impacted revenue growth in the fourth quarter of 2015. We did not offer to perform WellChec™ testing services during the three or six months ended June 30, 2016, and currently intend to restart performing such services in the three months ending December 31, 2016. Should additional contracts for services be received, WellChec™ will represent a greater portion of our overall revenues. However, we cannot predict with any certainty whether or not these order trends for WellChec™ will continue, nor the anticipated impact on other items of our results of operations.

 

Results of Operations

 

Three Months Ended June 30, 2016 Compared to Three Months Ended June 30, 2015

 

Revenue

 

We had revenue of $1,636,000 for the three months ended June 30, 2016, an increase of $333,000, or 26%, compared to $1,303,000 in the same period in 2015. Our revenue is primarily generated from per-use fees or leasing of our vascular testing systems. For licenses, we recognize revenue monthly for each unit installed with a customer. The average amount recognized each month per unit of product in the field is affected by the mix of units rented by direct customers or distributors, by price changes and by

 

 11 

  

discounts. The primary reason for the increase in revenue was that the total number of installed units in the field generating monthly revenue grew 20%, and the average amount of revenue recognized per unit increased 9% as compared to 2015. We believe that growth in the number of monthly invoices is predominately due to our sales and marketing efforts, which added new customers to an established customer base. Change in the average amount of revenue recognized per unit was due to changes in the mix of customers renting units. We recognized $51,000 of revenue from per-use fees, testing services and other sales during the three months ended June 30, 2016, an increase of $42,000, compared to $9,000 in the same period in 2015. We did not recognize any revenue from WellChec™ during the three months ended June 30, 2016, compared to $48,000 in the same period in 2015.

 

Operating expenses

 

We had total operating expenses of $2,506,000 for the three months ended June 30, 2016, a decrease of $114,000, or 4%, compared to $2,620,000 in the same period in 2015. The primary reasons for the decrease were decreased engineering and product development expense and sales and marketing expense, partially offset by an increase in cost of revenue and general and administrative expense. The changes in the various components of our operating expenses are described below.

 

Cost of revenue

 

We had cost of revenue of $533,000 for the three months ended June 30, 2016, an increase of $272,000, or 104%, from $261,000 for the same period in the previous year. The primary reasons for the increase were $75,000 of WellChec™ event expenses, an increase of $64,000 associated with employees who oversee manufacturing and fulfillment operations in connection with the growth in the number of units installed, and cost of units that were retired was $62,000 higher in light of migration of customers to QuantaFlo. A portion of the increase is also due to the fact that aggregate depreciation of our vascular testing systems for lease increased $15,000, or 23%, which corresponds to the 20% increase in the number of installed units in the field generating monthly depreciation charges and an increase in average depreciation per unit per month of 3%. Other cost of revenue items, such as freight and other miscellaneous items, were $32,000 higher, and depreciation of other capital assets was $24,000 higher in the second quarter of 2016 compared to the same period in 2015.

 

Engineering and product development expense

 

We had engineering and product development expense of $182,000 for the three months ended June 30, 2016, a decrease of $224,000, or 55%, compared to $406,000 in the same period in 2015. The decrease was primarily due to lower salary expense of $77,000, lower consulting costs for new product development of $66,000, lower clinical study expense of $59,000, and lower other expenses of $23,000, which were partially offset by an increase in stock-based compensation expense of $1,000.

 

Sales and marketing expense

 

We had sales and marketing expense of $1,028,000 for the three months ended June 30, 2016, a decrease of $260,000, or 20%, compared to $1,288,000 in the same period in 2015. The decrease was primarily due to lower salary expense of $71,000, lower sales commissions of $63,000, lower travel expense of $57,000, lower facility expense of $52,000, and lower trade show expense of $28,000, which decreases were partially offset by increased stock-based compensation expense of $7,000, and higher other expenses of $4,000 as compared to the same period in 2015.

 

General and administrative expense

 

We had general and administrative expense of $763,000 for the three months ended June 30 2016, an increase of $98,000, or 15%, compared to $665,000 in the same period in 2015. The increase was primarily due to higher costs associated with professional fees of $101,000, higher salaries and fees for employees, directors, and consultants of $31,000, higher stock-based compensation expense of $28,000, higher merchant fees and other expenses of $26,000, higher technical support of $8,000, and higher expense for uncollectable accounts of $2,000, which increases were partially offset by lower costs for taxes and associated expense of $71,000, lower patent and legal expenses of $14,000, lower insurance premium fees of $11,000, and lower travel expenses of $2,000.

 

Other expense

 

We had other expense of $96,000 for the three months ended June 30, 2016, an increase of $72,000, or 300%, compared to $24,000 in the same period in 2015. The increase was primarily due to higher interest expense of $71,000 associated with the issuance of promissory notes to lenders and higher credit card fees associated with our corporate credit card of $1,000.

 

 12 

 

Net loss

 

For the foregoing reasons, we had a net loss of $966,000, or $0.19 per share, for the three months ended June 30, 2016, a decrease of $375,000, or 28%, compared to a net loss of $1,341,000, or $0.27 per share, for the same period in 2015.

 

Six Months Ended June 30, 2016 Compared to Six Months Ended June 30, 2015

 

Revenue

 

We had revenue of $3,136,000 for the six months ended June 30, 2016, an increase of $631,000, or 25%, compared to $2,505,000 in the same period in 2015. Our revenue is primarily generated from per-use fees or leasing of our vascular testing systems. For licenses, we recognize revenue monthly for each unit installed with a customer. The average amount recognized each month per unit of product in the field is affected by the mix of units rented by direct customers or distributors, by price changes and by discounts. The primary reason for the increase in revenue was that the total number of installed units in the field generating monthly revenue grew 20%, and the average amount of revenue recognized per unit increased 10% as compared to 2015. We believe that growth in the number of monthly invoices is predominately due to our sales and marketing efforts, which added new customers to an established customer base. Change in the average amount of revenue recognized per unit was due to changes in the mix of customers renting units. We recognized $87,000 of revenue from per-use fees, testing services and other sales during the six months ended June 30, 2016, an increase of $78,000, compared to $9,000 in the same period in 2015. There was a reduction in revenue of $162,000 for WellChec™ testing services partially as an incentive to a customer to renew and expand an order for additional WellChec™ services from us in the six months ended June 30, 2016. We recognized $144,000 of revenue from providing testing services through our WellChec™ platform during the six months ended June 30, 2015.

 

Operating expenses

 

We had total operating expenses of $4,937,000 for the six months ended June 30, 2016, a decrease of $235,000, or 5%, compared to $5,172,000 in the same period in 2015. The primary reasons for the decrease were decreased engineering and product development expense and sales and marketing expense, partially offset by an increase in cost of revenue and general and administrative expense. The changes in the various components of our operating expenses are described below.

 

Cost of revenue

 

We had cost of revenue of $950,000 for the six months ended June 30, 2016, an increase of $448,000, or 89%, from $502,000 for the same period in the previous year. The primary reasons for the increase were an increase of $118,000 associated with employees who oversee manufacturing and fulfillment operations in connection with the growth in the number of units installed. In addition, we had $91,000 increase in cost of units retired as we migrate customers to our QuantaFlo product, and had $77,000 of higher WellChec™ event expenses. A portion of the increase is also due to the fact that aggregate depreciation of our vascular testing systems for lease increased $38,000, or 31%, which corresponds to the 20% increase in the number of installed units in the field generating monthly depreciation charges and an increase in average depreciation per unit per month of 3%. Other cost of revenue items, such as freight and other miscellaneous items, were $74,000 higher, and depreciation of other capital assets was $50,000 higher in the first six months of 2016 compared to the same period in 2015.

 

Engineering and product development expense

 

We had engineering and product development expense of $452,000 for the six months ended June 30, 2016, a decrease of $263,000, or 37%, compared to $715,000 in the same period in 2015. The decrease was primarily due to lower consulting costs for new product development of $122,000, lower clinical study expense of $111,000, decreased salary expense of $30,000, and lower other expenses of $11,000, which were partially offset by higher stock-based compensation expense of $11,000.

 

Sales and marketing expense

 

We had sales and marketing expense of $2,001,000 for the six months ended June 30, 2016, a decrease of $494,000, or 20%, compared to $2,495,000 in the same period in 2015. The decrease was primarily due to lower salary expense of $187,000, lower facility expense of $84,000, lower travel expense of $76,000, lower sales commissions of $73,000, lower trade show expense of $72,000, and lower other expenses of $19,000, which decreases were partially offset by increased stock-based compensation expense of $17,000 as compared to the same period in 2015.

 

 13 

 

General and administrative expense

 

We had general and administrative expense of $1,534,000 for the six months ended June 30 2016, an increase of $74,000, or 5%, compared to $1,460,000 in the same period in 2015. The increase was primarily due to higher costs associated with professional fees of $140,000, higher merchant fees and other expenses of $60,000, higher stock-based compensation expense of $43,000, higher technical support of $36,000, higher salaries and fees for employees, directors, and consultants of $18,000, which increases were partially offset by lower costs for taxes and associated expense of $135,000, lower expense for uncollectable accounts of $54,000, lower insurance premium fees of $24,000, lower patent and legal expenses of $6,000, and lower travel expenses of $4,000.

 

Other expense

 

We had other expense of $171,000 for the six months ended June 30, 2016, an increase of $125,000, or 272%, compared to $46,000 in the same period in 2015. The increase was primarily due to higher interest expense of $121,000 associated with the issuance of promissory notes to lenders and higher credit card fees associated with our corporate credit card of $4,000.

 

Net loss

 

For the foregoing reasons, we had a net loss of $1,972,000, or $0.38 per share, for the six months ended June 30, 2016, a decrease of $741,000, or 27%, compared to a net loss of $2,713,000, or $0.56 per share, for the same period in 2015.

 

Liquidity and Capital Resources

 

We had cash of $1,022,000 at June 30, 2016 compared to $405,000 at December 31, 2015, and total current liabilities of $3,280,000 at June 30, 2016 compared to $4,108,000 at December 31, 2015. As of June 30, 2016 we had negative working capital of approximately $1,525,000.

 

In January 2016, we borrowed an aggregate of $1,500,000 from Mr. William H.C. Chang pursuant to two separate promissory notes and also issued two 2-year warrants to acquire an aggregate 228,572 shares of our common stock at an exercise price of $1.75 per share. On March 31, 2016, we borrowed $700,000 from an accredited investor pursuant to a promissory note and also issued a 2-year warrant to acquire an aggregate 79,459 shares of our common stock at $1.85 per share. On April 5, 2016, we borrowed $160,000 from the same accredited investor pursuant to a promissory note and also issued a 2-year warrant to acquire an aggregate of 18,162 shares of our common stock at $1.85 per share. On May 20, 2016, we borrowed $80,000 from the same accredited investor pursuant to a promissory note and also issued a 2-year warrant to acquire an aggregate of 9,081 shares of our common stock at $1.85 per share. See “—Description of Indebtedness” for additional information regarding these loans.

 

We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our marketing and other promotional activities, research and continued development of our products and services. Our principal sources of cash have included the issuance of equity, including our February 2014 initial public offering of common stock, and to a lesser extent, recent private placement offerings of common stock, borrowings under loan agreements, the issuance of promissory notes, and revenue from leasing our product and selling our testing services. We expect that our operating expenses will continue to grow in order to grow our revenues and, as a result, we will need to generate significant additional net revenues to achieve profitability. For these reasons, our independent registered public accountants’ report for the year ended December 31, 2015 includes an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.” This doubt continues to exist.

 

Although we do not have any current capital commitments, we expect that we may increase our expenditures to continue our efforts to grow our business and commercialize our products and services. Accordingly, we currently expect to make additional expenditures in both sales and marketing, and invest in our corporate infrastructure. We also expect to invest in our research and development efforts. We do not have any definitive plans as to the exact amounts or particular uses at this time, and the exact amounts and timing of any expenditure may vary significantly from our current intentions. However, in order to execute on our business plan, and given our current available cash, we anticipate that we will need to raise additional capital. To improve operating cash flow, in 2015, we implemented measures to reduce expenses and renegotiated longer payment terms in our existing contracts. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on acceptable terms or whether or not we will generate sufficient revenues to become profitable and have positive operating cash flow. If we are unable to raise sufficient additional funds when necessary, we may need to curtail making additional expenditures and could be required to scale back our business plans, or make other changes until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

 

 14 

 

Operating activities

 

We used $1,540,000 of net cash in operating activities for the six months ended June 30, 2016. Non-cash adjustments to reconcile net loss to net cash used in operating activities plus changes in operating assets and liabilities provided $432,000 of cash in the six months ended June 30, 2016. These non-cash adjustments primarily reflect depreciation of $221,000, loss on disposal of assets for lease of $136,000, stock-based compensation expense of $135,000, amortization of debt discount costs of $84,000, and allowance for doubtful accounts of $18,000. Cash used in operating activities was primarily from trade accounts payable of $409,000, deferred revenue of $285,000, prepaid expenses and other current assets of $72,000, and accrued expenses of $49,000, partially offset by net cash provided by trade accounts receivable of $653,000.

 

For the same period in 2015, we used $2,422,000 of net cash in operating activities. Non-cash adjustments to reconcile net loss to net cash used in operating activities plus changes in operating assets and liabilities provided $291,000 of cash in the six months ended June 30, 2015. These non-cash adjustments primarily reflect depreciation of $129,000, allowance for doubtful accounts of $73,000, stock-based compensation expense of $63,000, loss on disposal of assets for lease of $44,000, and amortization of deferred financing costs and debt discounts of $37,000. Cash used in operating activities was primarily from deferred revenue of $132,000, partially offset by accounts payable of $27,000, accrued expenses of $21,000, trade accounts receivable of $20,000, and prepaid expenses and other current assets of $9,000.

 

Investing activities

 

We used $321,000 of net cash in investing activities for the six months ended June 30, 2016, primarily from purchases of assets for lease of $306,000 and fixed asset purchases of $15,000. We used $306,000 of net cash in investing activities for the same period in 2015, primarily for purchases of assets for lease of $261,000 and fixed asset purchases of $45,000.

 

Financing activities

 

We generated $2,478,000 in net cash in financing activities during the six months ended June 30, 2016 due to proceeds from loans payable. We generated $912,000 of net cash from financing activities during the same period in 2015, primarily from proceeds of $999,000 from the sale of shares of our common stock, $13,000 from exercise of stock options, partially offset by offering costs of $100,000.

 

Description of Indebtedness

 

In January 2016, we borrowed an aggregate of $1,500,000 from William H.C. Chang, a significant stockholder, pursuant to two separate 2-year promissory notes. The notes bear simple interest ($1.0 million at a rate of 10% per annum, and $0.5 million at 5% per annum) and mature in two years, with all principal and accrued but unpaid interest payable at maturity. We may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and we agreed not to incur additional indebtedness in excess of $50,000 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, we issued the Chang Family Trust a two-year warrant to purchase an aggregate of 228,372 shares of our common stock at an exercise price of $1.75 per share. The warrants may not be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 19.99% of our common stock.

 

In March 2016, we borrowed an aggregate of $700,000 from an accredited investor, pursuant to a two-year promissory note. The note bears simple interest at a rate of 10% per annum and matures in two years, with all principal and accrued but unpaid interest payable at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, we issued a two-year warrant to purchase an aggregate of 79,459 shares of our common stock at an exercise price of $1.85 per share. The warrants may not be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 4.99% of our common stock

 

In April 2016, we borrowed an aggregate of $160,000 from an accredited investor, pursuant to a two-year promissory note. The note bears simple interest at a rate of 10% per annum and matures in two years, with all principal and accrued but unpaid interest payable at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, we issued a two-year warrant to purchase an aggregate of 18,162 shares of our common stock at an exercise price of $1.85 per share. The warrants may not be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 4.99% of our common stock.

 

 15 

 

In May 2016, we borrowed an aggregate of $80,000 from an accredited investor, pursuant to a two-year promissory note. The note bears simple interest at a rate of 10% per annum and matures in two years, with all principal and accrued but unpaid interest payable at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, we issued a two-year warrant to purchase an aggregate of 9,081 shares of our common stock at an exercise price of $1.85 per share. The warrants may not be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 4.99% of our common stock.

 

See also Note 6 to our financial statements appearing elsewhere in this report for a description of our outstanding indebtedness.

 

Off-Balance Sheet Arrangements

 

As of each of June 30, 2016 and December 31, 2015, we had no off-balance sheet arrangements.

 

Commitments and Contingencies

 

As of each of June 30, 2016 and December 31, 2015, other than employment/consulting agreements with key executive officers and our facilities lease obligation, we had no material commitments other than the liabilities reflected in our financial statements.

 

JOBS Act

 

In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period, and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

In evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our chief executive officer and our vice president, finance, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q. Based on that evaluation, our chief executive officer and our vice president, finance concluded that our disclosure controls and procedures were not effective, at the reasonable assurance level as of the end of the period covered by that report, to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934 (1) is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (2) is accumulated and communicated to management, including our chief executive officer and our vice president, finance as appropriate to allow timely decisions regarding required disclosure, due to the existence of the material weaknesses in our internal control over financial reporting.  

 

Changes in Internal Control over Financial Reporting

 

In an effort to remediate the material weaknesses in our internal control over financial reporting, in early 2016 we began adopting and implementing policies and procedures with respect to the review, supervision, and monitoring of our accounting and reporting functions. We will continue assessing our procedures to improve our internal control over financial reporting. Other than these changes, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during our second fiscal quarter of 2016.

 

 16 

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Not applicable.

 

Item 1A. Risk Factors.

 

Not applicable.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

  

On April 5, 2016, in connection with the issuance of a two-year promissory note in the amount of $160,000, we issued to an accredited investor a two-year warrant to purchase an aggregate of 18,162 shares of our common stock at an exercise price of $1.85 per share. The warrants were issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act or pursuant to Regulation D.

 

On May 20, 2016, in connection with the issuance of a two-year promissory note in the amount of $80,000, we issued to an accredited investor a two-year warrant to purchase an aggregate of 9,081 shares of our common stock at an exercise price of $1.85 per share. The warrants were issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act or pursuant to Regulation D.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Not applicable.

 

Item 6. Exhibits.

 

Exh. No.   Exhibit Name
31.1   Rule 13a-14(a) Certification of Principal Executive Officer of Registrant
31.2   Rule 13a-14(a) Certification of Principal Financial Officer of Registrant
32   Section 1350 Certification
     
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema
101.CAL   XBRL Taxonomy Extension Calculation Linkbase
101.DEF   XBRL Taxonomy Extension Definition Linkbase
101.LAB   XBRL Taxonomy Extension Label Linkbase
101.PRE   XBRL Taxonomy Extension Presentation Linkbase

 

 17 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

August 2, 2016  SEMLER SCIENTIFIC, INC.
   
  By: /s/ Douglas Murphy-Chutorian, M.D.
    Douglas Murphy-Chutorian, M.D.
    Chief Executive Officer
     
  By: /s/ Daniel Conger
    Daniel Conger
    Vice-President, Finance
Principal Accounting Officer
 18 

 EX-31.1 2 t1601863_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, Douglas Murphy-Chutorian, M.D., certify that:

 

1.          I have reviewed this quarterly report on Form 10-Q of Semler Scientific, Inc., a Delaware corporation;

 

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.           The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Dated: August 2, 2016    
  /s/ Douglas Murphy-Chutorian, M.D.  
  Douglas Murphy-Chutorian, M.D  
  Chief Executive Officer  

 

 

 

 EX-31.2 3 t1601863_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

I, Daniel Conger, certify that:

 

1.           I have reviewed this quarterly report on Form 10-Q of Semler Scientific, Inc., a Delaware corporation;

 

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.           The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Dated: August 2, 2016  
   
  /s/  Daniel Conger  
  Daniel Conger, Vice-President, Finance
  (Principal Accounting Officer)

 

 

 

 EX-32 4 t1601863_ex32.htm EXHIBIT 32

 

Exhibit 32

 

SECTION 1350 CERTIFICATION

 

Each of the undersigned, Douglas Murphy-Chutorian, M.D., Chief Executive Officer of Semler Scientific, Inc., a Delaware corporation (the “Company”), and Daniel Conger, Vice-President, Finance of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge (1) the quarterly report on Form 10-Q of the Company for the three months ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ Douglas Murphy-Chutorian, M.D.
  Name: Douglas Murphy-Chutorian, M.D.
  Title: Chief Executive Officer
  Dated: August 2, 2016
   
  /s/  Daniel Conger
  Name: Daniel Conger
 

Title: Vice-President, Finance

(Principal Accounting Officer)

  Dated: August 2, 2016

 

This certification accompanies and is being “furnished” with this Report, shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 EX-101.INS 5 smlr-20160630.xml XBRL INSTANCE FILE 0001554859 smlr:LeaseAgreementMember 2014-09-01 2014-09-23 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember 2014-12-30 2015-01-31 0001554859 2015-04-01 2015-06-30 0001554859 us-gaap:WarrantMember 2015-04-01 2015-06-30 0001554859 us-gaap:EmployeeStockOptionMember 2015-04-01 2015-06-30 0001554859 us-gaap:CostOfSalesMember 2015-04-01 2015-06-30 0001554859 smlr:EngineeringAndProductDevelopmentMember 2015-04-01 2015-06-30 0001554859 us-gaap:SellingAndMarketingExpenseMember 2015-04-01 2015-06-30 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0001554859 us-gaap:MinimumMember 2015-01-01 2015-06-30 0001554859 2015-01-01 2015-06-30 0001554859 us-gaap:WarrantMember 2015-01-01 2015-06-30 0001554859 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0001554859 us-gaap:CostOfSalesMember 2015-01-01 2015-06-30 0001554859 smlr:EngineeringAndProductDevelopmentMember 2015-01-01 2015-06-30 0001554859 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-06-30 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0001554859 us-gaap:MaximumMember 2015-01-01 2015-06-30 0001554859 smlr:SubLeaseAgreementMember 2015-07-01 2015-07-15 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember 2015-10-01 2015-10-31 0001554859 2015-01-01 2015-12-31 0001554859 2015-12-31 0001554859 us-gaap:UnsecuredDebtMember smlr:FixedInterestRateOf10PercentMember 2016-01-15 0001554859 us-gaap:UnsecuredDebtMember smlr:FixedInterestRateOf10PercentMember 2016-01-02 2016-01-15 0001554859 us-gaap:UnsecuredDebtMember smlr:FixedInterestRateOfFivePercentMember 2016-01-21 0001554859 us-gaap:UnsecuredDebtMember smlr:FixedInterestRateOfFivePercentMember 2016-01-02 2016-01-21 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember 2015-12-25 2016-01-31 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember smlr:NonEmployeeDirectorMember 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember smlr:NonEmployeeDirectorMember 2016-02-01 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember us-gaap:BoardOfDirectorsChairmanMember 2016-02-01 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember us-gaap:BoardOfDirectorsChairmanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-02-01 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember us-gaap:BoardOfDirectorsChairmanMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2016-02-01 2016-02-18 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember us-gaap:BoardOfDirectorsChairmanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-02-01 2016-02-18 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-03-31 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-03-01 2016-03-31 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-04-05 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-04-01 2016-04-05 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-05-20 0001554859 us-gaap:InvestorMember smlr:FixedInterestRateOf10PercentMember us-gaap:UnsecuredDebtMember 2016-05-01 2016-05-20 0001554859 2016-04-01 2016-06-30 0001554859 us-gaap:WarrantMember 2016-04-01 2016-06-30 0001554859 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0001554859 us-gaap:CostOfSalesMember 2016-04-01 2016-06-30 0001554859 smlr:EngineeringAndProductDevelopmentMember 2016-04-01 2016-06-30 0001554859 us-gaap:SellingAndMarketingExpenseMember 2016-04-01 2016-06-30 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001554859 us-gaap:MaximumMember 2016-04-01 2016-06-30 0001554859 us-gaap:MinimumMember 2016-04-01 2016-06-30 0001554859 2016-01-01 2016-06-30 0001554859 us-gaap:WarrantMember 2016-01-01 2016-06-30 0001554859 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001554859 us-gaap:CostOfSalesMember 2016-01-01 2016-06-30 0001554859 smlr:EngineeringAndProductDevelopmentMember 2016-01-01 2016-06-30 0001554859 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-06-30 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001554859 us-gaap:MaximumMember 2016-01-01 2016-06-30 0001554859 us-gaap:MinimumMember 2016-01-01 2016-06-30 0001554859 smlr:LeaseTermFromFebruary2015ToJanuary2016Member smlr:LeaseAgreementMember 2016-01-01 2016-06-30 0001554859 smlr:LeaseTermFromFebruary2016ToJanuary2017Member smlr:LeaseAgreementMember 2016-01-01 2016-06-30 0001554859 smlr:LeaseTermFromFebruary2017ToJanuary2018Member smlr:LeaseAgreementMember 2016-01-01 2016-06-30 0001554859 smlr:LeaseTermFromAugust2015ToJuly2016Member smlr:SubLeaseAgreementMember 2016-01-01 2016-06-30 0001554859 smlr:LeaseTermFromAugust2016ToJuly2017Member smlr:SubLeaseAgreementMember 2016-01-01 2016-06-30 0001554859 smlr:LeaseTermFromAugust2017ToJuly2018Member smlr:SubLeaseAgreementMember 2016-01-01 2016-06-30 0001554859 2016-06-30 0001554859 smlr:LeaseAgreementMember 2016-06-30 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember 2016-06-30 0001554859 smlr:SubLeaseAgreementMember 2016-06-30 0001554859 smlr:StockIncentivePlan2014Member us-gaap:EmployeeStockOptionMember us-gaap:BoardOfDirectorsChairmanMember 2016-02-18 0001554859 smlr:KeyPersonStockOptionPlan2007Member us-gaap:EmployeeStockOptionMember 2016-06-30 0001554859 2016-07-29 0001554859 2014-12-31 0001554859 2015-06-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure Semler Scientific, Inc. 0001554859 smlr --12-31 Smaller Reporting Company 5123568 10-Q 2016-06-30 false 2016 Q2 1303000 2505000 1636000 3136000 261000 502000 533000 950000 406000 715000 182000 452000 1288000 2495000 1028000 2001000 665000 1460000 763000 1534000 2620000 5172000 2506000 4937000 -1317000 -2667000 -870000 -1801000 -1341000 -2713000 -966000 -1972000 -0.27 -0.56 -0.19 -0.38 4978878 4871614 5123568 5123568 405000 1022000 4156000 2340000 1278000 607000 69000 126000 1752000 1755000 830000 839000 497000 452000 15000 3079000 3061000 839000 430000 2317000 2183000 952000 667000 4108000 3280000 43000 43000 85000 883000 43000 2312000 5000 5000 21291000 21804000 -22368000 -24340000 -1072000 -2531000 3079000 3061000 183000 94000 0 95000 0.001 0.001 50000000 50000000 5148568 5148568 5123568 5123568 25000 25000 37000 84000 129000 221000 -44000 -136000 73000 18000 63000 135000 -20000 -653000 -9000 72000 27000 -409000 21000 -49000 -132000 -285000 -2422000 -1540000 45000 15000 261000 306000 -306000 -321000 999000 2478000 912000 2478000 -1816000 617000 13000 363000 <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 79px;"><font style="font-size: 10pt;"><b>1.</b></font></td> <td style="width: 1488px;"><font style="font-size: 10pt;"><b>Basis of Presentation</b></font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Semler Scientific, Inc., a Delaware corporation (&#8220;Semler&#8221; or &#8220;the Company&#8221;), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K filed with the SEC on February 26, 2016 (the &#8220;Annual Report&#8221;). The balance sheet as of December&#160;31, 2015 included in this report has been derived from the audited financial statements included in the Annual Report. In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year. Items in prior period financial statements have been adjusted to conform with the current period presentation.</div> </div> <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 79px;"><font style="font-size: 10pt;"><b>2.</b></font></td> <td style="width: 1488px; text-align: justify;"><font style="font-size: 10pt;"><b>Going Concern</b></font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company has incurred recurring losses since inception and expects to continue to incur losses as a result of costs and expenses related to the Company&#8217;s marketing and other promotional activities, research and continued development of its product. As of June 30, 2016, the Company has negative working capital of $1,525, cash of $1,022 and stockholders&#8217; deficit of $2,531. The Company&#8217;s principal sources of cash have included the issuance of equity securities, borrowings under loan agreements, revenue from leasing its product and providing testing services. To increase revenue, the Company&#8217;s operating expenses will continue to grow and, as a result, the Company will need to generate significant additional revenue to achieve profitability.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s financial statements as of and for the three and six months ended June 30, 2016 have been prepared under the assumption that the Company will continue as a going concern. The Company&#8217;s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate additional revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company can give no assurances that additional capital that the Company is able to obtain, if any, will be sufficient to meet the Company&#8217;s needs. If the Company is unable to raise additional capital or increase revenue from leasing its product and providing testing services within the next twelve months to continue to fund operations at its current cash expenditure levels, the Company&#8217;s operations will need to be curtailed. The foregoing conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</div> </div> <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 79px;"><font style="font-size: 10pt;"><b>3.</b></font></td> <td style="width: 1488px;"><font style="font-size: 10pt;"><b>Assets for Lease, net</b></font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Assets for lease consist of the following:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 70%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">June 30,&#160;<br />2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">December 31,&#160;<br />2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 870px; text-align: left;">Assets for lease</td> <td style="width: 12px;">&#160;</td> <td style="width: 12px; text-align: left;">$</td> <td style="width: 118px; text-align: right;">1,333</td> <td style="width: 12px; text-align: left;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 117px; text-align: right;">1,280</td> <td style="width: 11px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated Depreciation</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(494</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(450</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 2.5pt;">Assets for lease, net</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">839</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">830</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Depreciation expense amounted to $81 and $66 for the three months ended June 30, 2016 and June 30, 2015, respectively. Depreciation expense amounted to $161 and $123 for the six months ended June 30, 2016 and June 30, 2015, respectively. Reduction to accumulated depreciation for returned items was $88 and $27 for the three months ended June 30, 2016 and June 30, 2015, respectively. Reduction to accumulated depreciation for returned items was $117 and $41 for the six months ended June 30, 2016 and June 30, 2015, respectively.</div> </div> <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 79px;"><font style="font-size: 10pt;"><b>4.</b></font></td> <td style="width: 1488px;"><font style="font-size: 10pt;"><b>Property and Equipment, net</b></font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Property and equipment, net consists of the following:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 70%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">June 30,&#160;<br />2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">December 31,&#160;<br />2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 870px; text-align: left;">Property and equipment</td> <td style="width: 12px;">&#160;</td> <td style="width: 12px; text-align: left;">$</td> <td style="width: 118px; text-align: right;">557</td> <td style="width: 12px; text-align: left;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 117px; text-align: right;">542</td> <td style="width: 11px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(105</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(45</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 2.5pt;">Property and equipment, net</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">452</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">497</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Depreciation expense amounted to $30 and $4 for the three months ended June 30, 2016 and 2015, respectively. Depreciation expense amounted to $60 and $6 for the six months ended June 30, 2016 and 2015, respectively.</div> </div> <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 79px;"><font style="font-size: 10pt;"><b>5.</b></font></td> <td style="width: 1488px;"><font style="font-size: 10pt;"><b>Accrued Expenses</b></font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accrued expenses consist of the following:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 70%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">June 30,&#160;<br />2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">December 31,&#160;<br />2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 870px; text-align: left;">Offering Costs</td> <td style="width: 12px;">&#160;</td> <td style="width: 12px; text-align: left;">$</td> <td style="width: 118px; text-align: right;">227</td> <td style="width: 12px; text-align: left;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 117px; text-align: right;">227</td> <td style="width: 11px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Compensation</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,436</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,093</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 1pt;">Miscellaneous Accruals</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">520</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">997</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total Accrued Expenses</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,183</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,317</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.35pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: -0.35pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accumulated offering costs that were accrued pertain to consulting fees associated with securing equity financing for the Company prior to the initial public offering. Prior to becoming Chief Executive Officer (&#8220;CEO&#8221;), the Company&#8217;s current CEO performed consulting services for the Company, which included managing finance, sales, marketing, operational and strategic planning for the Company, as well as assistance and strategic guidance in securing financing. The Company has agreed to a payment date of December 31, 2016 for these fees.</div> </div> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 36px;"><font style="font-size: 10pt;"><b>6.</b></font></td> <td><font style="font-size: 10pt;"><b>Commitments and Contingencies</b></font></td> </tr> </table> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Facilities Leases</b></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Facilities lease expense recognized by the Company was $22&#160;and $65&#160;for the three months ended June 30, 2016 and 2015, respectively. Facilities lease expense recognized by the Company was $37&#160;and $101&#160;for the six months ended June 30, 2016 and 2015, respectively.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On September 23, 2014, the Company entered into a 36-month lease agreement for office space for the sales and marketing team located in Menlo Park, CA. The lease term commenced February 1, 2015 and is effective through January 31, 2018. Payments required under the terms of the lease are $17.0 per month from February 2015 to January 2016, $17.5 per month from February 2016 to January 2017, and $18.0 per month from February 2017 to January 2018. The Company anticipates total future lease payments of $104.8 for the year ended December 31, 2016; $215.4 for the year ended December 31, 2017; and $18.0 for the year ended December 31, 2018. On July 15, 2015, the Company entered into a 30-month sublease agreement for the Menlo Park office space, which commenced August 1, 2015 and is effective through the term of the lease, January 31, 2018. Payments required to the Company under the terms of the sublease are $15.5 per month from August 2015 to July 2016,</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">$16.0 per month from August 2016 to July 2017, and $16.5 per month from August 2017 to January 2018. The Company anticipates receipt of total future sublease payments of $95.5 for the year ended December 31, 2016; $194.4 for the year ended December 31, 2017; and $16.5 for the year ended December 31, 2018.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Loans Payable</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Loans from Related Parties</i><i>&#160;</i></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On January 15, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $1,000 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $1,000 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender&#8217;s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company&#8217;s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company&#8217;s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On January 21, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $500 unsecured loan for a 24-month term at a fixed interest rate of 5% p.a. Under the loan agreement, the Company will pay $500 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender&#8217;s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company&#8217;s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company&#8217;s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Other Loans</i></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On March 31, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $700 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $700 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 79,459 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company&#8217;s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company&#8217;s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On April 5, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $160 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $160 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 18,162 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company&#8217;s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company&#8217;s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On May 20, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $80 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $80 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Company issued the accredited investor a two-year warrant to purchase 9,081 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company&#8217;s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company&#8217;s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company uses the Black-Scholes pricing model to determine the relative fair market value of warrants. The relative fair market value of each warrant is estimated on the date of grant. The relative fair value of the warrants granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented:</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 95%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"><font style="font-size: 8pt;">Three months ended<br />June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"><font style="font-size: 8pt;">Six months ended June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 707px;">Expected term (in years)</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 148px;">2</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 148px;">-</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="text-align: right; width: 147px;">2</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="text-align: right; width: 147px;">-</td> <td style="text-align: left; width: 14px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">0.73 &#8211; 0.89</font></td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">0.73 &#8211; 0.89</font></td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Expected volatility</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">98.1 &#8211; 99.0</font></td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">97.7 &#8211; 99.0</font></td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Expected dividend rate.</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The assumptions are based on the following for each of the years presented:</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Valuation Method</i>&#160;&#8212; The Company estimates the relative fair value of warrants using the Black-Scholes pricing model.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Expected Term</i>&#160;&#8212; The Company uses the amount of time the warrants are exercisable per the contractual terms of the award.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Volatility</i>&#160;&#8212; Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the warrants.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Risk-free Interest Rate</i>&#160;&#8212; The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the warrants.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Expected Dividend&#160;</i>&#8212; The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">For the three months ended June 30, 2016 and 2015 interest expense was $96 and $25, respectively. Of this total interest expense, the portion related to amortization of debt discount was $48 and $19, respectively. For the six months ended June 30, 2016 and 2015 interest expense was $170 and $49, respectively. Of this total interest expense, the portion related to amortization of debt discount was $84 and $37, respectively.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Indemnification Obligations</i></b></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27.35pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27.35pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company&#8217;s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company&#8217;s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27.35pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.</p> <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 79px;"><font style="font-size: 10pt;"><b>7.</b></font></td> <td style="width: 1488px;"><font style="font-size: 10pt;"><b>Net Loss Per Common Share</b></font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Because the Company was in a loss position for each of the periods presented, diluted net loss per share is the same as basic net loss per share for each period as the inclusion of all potential common shares outstanding would have been anti-dilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.4in; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"><font style="font-size: 8pt;">Three months ended<br />June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"><font style="font-size: 8pt;">Six months ended<br />June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td>Weighted average shares outstanding:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 639px; text-align: left;">Common stock warrants</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 134px; text-align: right;">706,331</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 133px; text-align: right;">359,714</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 133px; text-align: right;">645,353</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 133px; text-align: right;">359,714</td> <td style="width: 13px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding-bottom: 1pt;">Options</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2,069,911</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">736,722</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2,027,480</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">727,069</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,776,242</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">1,096,436</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,672,833</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">1,086,783</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div> </div> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 79px;"><font style="font-size: 10pt;"><b>8.</b></font></td> <td style="width: 1488px;"><font style="font-size: 10pt;"><b>Stock Option Plan</b></font></td> </tr> </table> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s stock-based compensation program is designed to attract and retain employees while also aligning employees' interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (&#8220;2007 Plan&#8221;) or the stockholder-approved 2014 Stock Incentive Plan (&#8220;2014 Plan&#8221;). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the &#8220;Share Reserve&#8221;), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company&#8217;s Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. On January 1, 2015, the Share Reserve increased by 188,640 shares due to the automatic 4% increase. On January 1, 2016, the Share Reserve increased by 204,943 shares due to the automatic 4% increase. The Share Reserve is currently 2,343,583 shares for the year ending December 31, 2016.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of June 30, 2016, 0 shares of an aggregate total of 407,500 shares were available for future stock-based compensation grants under the 2007 Plan and 666,121 shares of an aggregate total of 2,343,583 shares were available for future stock-based compensation grants under the 2014 Plan.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Aggregate intrinsic value represents the difference between the closing market value as of June 30, 2016 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company&#8217;s stock option activity and related information for the six months ended June 30, 2016 is as follows:</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 95%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14"><font style="font-size: 8pt;">Options&#160;Outstanding</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Number&#160;of<br />Stock Options<br />Outstanding</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Weighted<br />Average<br />Exercise&#160;Price</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term&#160;(In Years)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Aggregate<br />Intrinsic&#160;Value<br />&#160;(in thousands)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="width: 707px; font-weight: bold;">Balance, January 1, 2016</td> <td style="width: 15px; font-weight: bold;">&#160;</td> <td style="text-align: left; width: 15px; font-weight: bold;">&#160;</td> <td style="text-align: right; width: 148px; font-weight: bold;">1,909,911</td> <td style="text-align: left; width: 15px; font-weight: bold;">&#160;</td> <td style="width: 15px; font-weight: bold;">&#160;</td> <td style="text-align: left; width: 15px; font-weight: bold;">$</td> <td style="text-align: right; width: 148px; font-weight: bold;">2.58</td> <td style="text-align: left; width: 15px; font-weight: bold;">&#160;</td> <td style="width: 15px; font-weight: bold;">&#160;</td> <td style="text-align: left; width: 14px; font-weight: bold;">&#160;</td> <td style="text-align: right; width: 147px; font-weight: bold;">8.56</td> <td style="text-align: left; width: 14px; font-weight: bold;">&#160;</td> <td style="width: 14px; font-weight: bold;">&#160;</td> <td style="text-align: left; width: 14px; font-weight: bold;">$</td> <td style="text-align: right; width: 147px; font-weight: bold;">813</td> <td style="text-align: left; width: 14px; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Options granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">160,000</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2.23</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Options exercised</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Options forfeited/canceled</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">394</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3.44</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="font-weight: bold;">Balance, June 30, 2016</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="text-align: right; font-weight: bold;">2,069,517</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">2.58</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="text-align: right; font-weight: bold;">8.18</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">280</td> <td style="text-align: left; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="font-weight: bold;">Exercisable as of June 30, 2016</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="text-align: right; font-weight: bold;">1,581,140</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">2.61</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="text-align: right; font-weight: bold;">7.92</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">280</td> <td style="text-align: left; font-weight: bold;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The total compensation cost related to unvested stock option awards not yet recognized was $802 as of June 30, 2016. The weighted average period over which the total unrecognized compensation cost related to these unvested stock awards will be recognized is 2.77 years.&#160;<font style="color: #231f20;">The estimated&#160;fair value of option shares vested during the quarters ended</font>&#160;<font style="color: #231f20;">June 30, 2016 and 2015 was $66 and $31, respectively. The estimated&#160;fair value of option shares vested during the six months ended</font>&#160;<font style="color: #231f20;">June 30, 2016 and 2015 was $135 and $63, respectively. The weighted average fair value of options granted during the quarter ended June 30, 2015 was $2.32 per share, or an aggregate grant date fair value of $116, respectively</font>. There were no options granted during the quarter ended June 30, 2016.&#160;<font style="color: #231f20;">The weighted average&#160;fair value of options granted during the six months ended June 30, 2016 and 2015 was $1.43 per share and $1.75 per share, respectively, or an aggregate grant date fair value of $229 and $219, respectively</font>.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 19.95pt; margin: 0pt 0px 0pt 5.85pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On February 18, 2016 the Compensation Committee of the Company&#8217;s Board of Directors granted, and the full Board ratified, an option to acquire an aggregate of 125,000 shares under the 2014 Plan to the Company&#8217;s CEO. This option vests 25% on the one-year anniversary of the grant date and monthly thereafter for 36 months, such that the option is vested in full on the four-year anniversary of the grant date. On February 18, 2016 the Company&#8217;s Compensation Committee granted, and the full Board ratified, options to each of the then-seated non-employee Directors to acquire 5,000 shares, for an aggregate of 35,000 shares, under the 2014 Plan. These options vest on the one-year anniversary of their grant date.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Determining the Fair Value of Stock Options</b></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company uses the Black-Scholes pricing model to determine the fair value of stock options. The fair value of each option grant is estimated on the date of the grant. The following assumptions for the periods presented were:</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 95%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"><font style="font-size: 8pt;">Three months ended<br />June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"><font style="font-size: 8pt;">Six months ended June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 707px;">Expected term (in years)</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 148px;">-</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 148px;">5</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="text-align: right; width: 147px;">5</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="text-align: right; width: 147px;">5</td> <td style="text-align: left; width: 14px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.6</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.21</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">1.5 &#8211; 1.6</font></td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Expected volatility</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">82.5</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">80.4</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">82.5 &#8211; 83.3</font></td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Expected dividend rate.</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> </tr> </table> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The assumptions are based on the following for each of the years presented:</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Valuation Method</i>&#160;&#8212; The Company estimates the fair value of its stock options using the Black-Scholes option pricing model.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Expected Term</i>&#160;&#8212; The Company estimates the expected term consistent with the simplified method identified by the SEC. The Company elected to use the simplified method because of its limited history of stock option exercise activity and its stock options meet the criteria of the &#8220;plain-vanilla&#8221; options as defined by the SEC. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;<i>Volatility</i>&#160;&#8212; Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the options.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Risk-free Interest Rate</i>&#160;&#8212; The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Expected Dividend&#160;</i>&#8212; The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Forfeiture</i>&#160;&#8212; The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of the awards, which are generally the vesting periods. If the Company&#8217;s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company has recorded an expense of $66 and $31 as it relates to stock-based compensation for the three months ended June 30, 2016 and 2015, respectively. The Company has recorded an expense of $135 and $63 as it relates to stock-based compensation for the six months ended June 30, 2016 and 2015, respectively, which was allocated as follows based on the role and responsibility of the recipient in the Company:</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 27pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 95%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"><font style="font-size: 8pt;">Three months&#160;ended June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"><font style="font-size: 8pt;">Six months ended June 30</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="width: 707px;">Cost of Revenue</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 148px;">1</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 148px;">1</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 147px;">1</td> <td style="text-align: left; width: 14px;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 147px;">1</td> <td style="text-align: left; width: 14px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Engineering and Product Development</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">18</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Sales and Marketing</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">17</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">10</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">42</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">25</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">General and Administrative</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">43</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">15</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">74</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">30</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">66</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">31</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">135</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">63</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 79px;"><font style="font-size: 10pt;"><b>9.</b></font></td> <td style="width: 1488px;"><font style="font-size: 10pt;"><b>Subsequent Events</b></font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 22.5pt; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">None.</p> <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 1488px;"><font style="font-size: 10pt;"><b>Basis of Presentation</b></font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Semler Scientific, Inc., a Delaware corporation (&#8220;Semler&#8221; or &#8220;the Company&#8221;), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K filed with the SEC on February 26, 2016 (the &#8220;Annual Report&#8221;). The balance sheet as of December&#160;31, 2015 included in this report has been derived from the audited financial statements included in the Annual Report. In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year. Items in prior period financial statements have been adjusted to conform with the current period presentation.</div> </div> <div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 70%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">June 30,&#160;<br />2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">December 31,&#160;<br />2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 870px; text-align: left;">Assets for lease</td> <td style="width: 12px;">&#160;</td> <td style="width: 12px; text-align: left;">$</td> <td style="width: 118px; text-align: right;">1,333</td> <td style="width: 12px; text-align: left;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 117px; text-align: right;">1,280</td> <td style="width: 11px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated Depreciation</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(494</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(450</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 2.5pt;">Assets for lease, net</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">839</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">830</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> </div> <div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 70%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">June 30,&#160;<br />2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">December 31,&#160;<br />2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 870px; text-align: left;">Property and equipment</td> <td style="width: 12px;">&#160;</td> <td style="width: 12px; text-align: left;">$</td> <td style="width: 118px; text-align: right;">557</td> <td style="width: 12px; text-align: left;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 117px; text-align: right;">542</td> <td style="width: 11px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(105</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(45</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 2.5pt;">Property and equipment, net</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">452</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">497</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> </div> <div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 70%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">June 30,&#160;<br />2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">December 31,&#160;<br />2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 870px; text-align: left;">Offering Costs</td> <td style="width: 12px;">&#160;</td> <td style="width: 12px; text-align: left;">$</td> <td style="width: 118px; text-align: right;">227</td> <td style="width: 12px; text-align: left;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 117px; text-align: right;">227</td> <td style="width: 11px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Compensation</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,436</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,093</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 1pt;">Miscellaneous Accruals</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">520</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">997</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total Accrued Expenses</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,183</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,317</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> </div> <div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"><font style="font-size: 8pt;">Three months ended<br />June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"><font style="font-size: 8pt;">Six months ended June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 707px; text-align: left;">Expected term (in years)</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 148px; text-align: right;">2</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 148px; text-align: right;">-</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 147px; text-align: right;">2</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 147px; text-align: right;">-</td> <td style="width: 14px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">0.73 &#8211; 0.89</font></td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">0.73 &#8211; 0.89</font></td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Expected volatility</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">98.1 &#8211; 99.0</font></td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">97.7 &#8211; 99.0</font></td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Expected dividend rate.</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> </table> </div> <div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"><font style="font-size: 8pt;">Three months ended<br />June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6" nowrap="nowrap"><font style="font-size: 8pt;">Six months ended<br />June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td>Weighted average shares outstanding:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 639px; text-align: left;">Common stock warrants</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 134px; text-align: right;">706,331</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 133px; text-align: right;">359,714</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 133px; text-align: right;">645,353</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 133px; text-align: right;">359,714</td> <td style="width: 13px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding-bottom: 1pt;">Options</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2,069,911</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">736,722</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">2,027,480</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">727,069</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,776,242</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">1,096,436</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">2,672,833</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">1,086,783</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> </div> <p style="text-align: center; widows: 1; text-transform: none; margin-top: 0pt; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; margin-bottom: 0pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 95%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14"><font style="font-size: 8pt;">Options&#160;Outstanding</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Number&#160;of<br />Stock Options<br />Outstanding</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Weighted<br />Average<br />Exercise&#160;Price</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term&#160;(In Years)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Aggregate<br />Intrinsic&#160;Value<br />&#160;(in thousands)</font></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="width: 707px; font-weight: bold;">Balance, January 1, 2016</td> <td style="width: 15px; font-weight: bold;">&#160;</td> <td style="text-align: left; width: 15px; font-weight: bold;">&#160;</td> <td style="text-align: right; width: 148px; font-weight: bold;">1,909,911</td> <td style="text-align: left; width: 15px; font-weight: bold;">&#160;</td> <td style="width: 15px; font-weight: bold;">&#160;</td> <td style="text-align: left; width: 15px; font-weight: bold;">$</td> <td style="text-align: right; width: 148px; font-weight: bold;">2.58</td> <td style="text-align: left; width: 15px; font-weight: bold;">&#160;</td> <td style="width: 15px; font-weight: bold;">&#160;</td> <td style="text-align: left; width: 14px; font-weight: bold;">&#160;</td> <td style="text-align: right; width: 147px; font-weight: bold;">8.56</td> <td style="text-align: left; width: 14px; font-weight: bold;">&#160;</td> <td style="width: 14px; font-weight: bold;">&#160;</td> <td style="text-align: left; width: 14px; font-weight: bold;">$</td> <td style="text-align: right; width: 147px; font-weight: bold;">813</td> <td style="text-align: left; width: 14px; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Options granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">160,000</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2.23</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Options exercised</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Options forfeited/canceled</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">394</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3.44</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="font-weight: bold;">Balance, June 30, 2016</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="text-align: right; font-weight: bold;">2,069,517</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">2.58</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="text-align: right; font-weight: bold;">8.18</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">280</td> <td style="text-align: left; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="font-weight: bold;">Exercisable as of June 30, 2016</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="text-align: right; font-weight: bold;">1,581,140</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">2.61</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="text-align: right; font-weight: bold;">7.92</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">$</td> <td style="text-align: right; font-weight: bold;">280</td> <td style="text-align: left; font-weight: bold;">&#160;</td> </tr> </table> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"><font style="font-size: 8pt;">Three months ended<br />June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"><font style="font-size: 8pt;">Six months ended June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 707px; text-align: left;">Expected term (in years)</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 148px; text-align: right;">-</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 148px; text-align: right;">5</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 147px; text-align: right;">5</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 147px; text-align: right;">5</td> <td style="width: 14px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.6</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.21</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">1.5 &#8211; 1.6</font></td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Expected volatility</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">82.5</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">80.4</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">82.5 &#8211; 83.3</font></td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Expected dividend rate.</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> </tr> </table> <div>&#160;</div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.38in; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"><font style="font-size: 8pt;">Three months&#160;ended June 30,</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"><font style="font-size: 8pt;">Six months ended June 30</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2016</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 8pt;">2015</font></td> <td style="padding-bottom: 1pt; font-weight: bold;"><font style="font-size: 8pt;">&#160;</font></td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 707px;">Cost of Revenue</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 148px; text-align: right;">1</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 148px; text-align: right;">1</td> <td style="width: 15px; text-align: left;">&#160;</td> <td style="width: 15px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 147px; text-align: right;">1</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 147px; text-align: right;">1</td> <td style="width: 14px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Engineering and Product Development</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">18</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left;">Sales and Marketing</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">17</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">10</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">42</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">25</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">General and Administrative</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">43</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">15</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">74</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">30</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">66</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">31</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">135</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">63</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <div><br class="apple-interchange-newline" />&#160;</div> -1525000 1280000 1333000 450000 494000 66000 123000 81000 161000 27000 41000 88000 117000 542000 557000 45000 105000 4000 6000 30000 60000 227000 227000 1093000 1436000 997000 520000 P2Y P2Y 0.0089 0.0073 0.0089 0.0073 0.990 0.981 0.990 0.977 0.00 0.00 P36M P30M 17000 17500 18000 15500 16000 16500 104800 95500 215400 194400 18000 16500 P24M P24M P24M P24M P24M 1000000 500000 700000 160000 80000 0.10 0.05 0.1000 0.1000 0.10 1000000 500000 700000 160000 80000 50000 50000 114286 114286 79459 18162 9081 1.75 1.75 1.85 1.85 1.85 P2Y P2Y P2Y P2Y P2Y more than 19.99% more than 19.99% more than 4.99% more than 4.99% more than 4.99% 25000 49000 96000 170000 1096436 359714 736722 1086783 359714 727069 2776242 706331 2069911 2672833 645353 2027480 1909911 2069517 5000 160000 394 1581140 2.58 2.58 2.23 3.44 2.61 P8Y6M22D P8Y2M5D P7Y11M1D 813000 280000 280000 P5Y P5Y P5Y 0.016 0.015 0.016 0.0121 0.825 0.825 0.833 0.804 0.00 0.00 0.00 31000 1000 5000 10000 15000 63000 1000 7000 25000 30000 66000 1000 5000 17000 43000 135000 1000 18000 42000 74000 0.04 0.04 0.04 666121 0 35000 125000 407500 188640 1500000 204943 P10Y 802000 P2Y9M7D 31000 63000 66000 135000 2.32 1.75 1.43 116000 219000 229000 0.25 P36M P4Y P1Y -24000 -46000 -96000 -171000 13000 100000 65000 101000 22000 37000 19000 37000 48000 84000 0001554859us-gaap:EmployeeStockOptionMembersmlr:StockIncentivePlan2014Member2016-01-012016-06-30 2343583 450000 1301000 199000 EX-101.SCH 6 smlr-20160630.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Assets for Lease, net link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property and Equipment, net link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Net Loss Per Common Share link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Stock Option Plan link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Summary of Significant Accounting Policies and Estimates (Policies) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Assets for lease, net (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Stock Option Plan (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Going Concern (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Assets for Lease, net - Summary of assets for lease (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Assets for Lease, net (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Property and Equipment, net (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Accrued Expenses - Summary of accrued expenses (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Commitments and Contingencies (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Commitments and Contingencies (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Stock Option Plan - Summary of stock-based compensation activity (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Stock Option Plan - Weighted-average Black-Scholes fair value assumptions (Details 1) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Stock Option Plan - Stock-based compensation (Details 2) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Stock Option Plan (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Stock Option Plan (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 smlr-20160630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 smlr-20160630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 smlr-20160630_lab.xml XBRL LABEL FILE EX-101.PRE 10 smlr-20160630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2016
Jul. 29, 2016
Document And Entity Information [Abstract]    
Entity Registrant Name Semler Scientific, Inc.  
Entity Central Index Key 0001554859  
Trading Symbol smlr  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   5,123,568
Document Type 10-Q  
Document Period End Date Jun. 30, 2016  
Amendment Flag false  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Income Statement [Abstract]        
Revenue $ 1,636 $ 1,303 $ 3,136 $ 2,505
Operating expenses:        
Cost of revenue 533 261 950 502
Engineering and product development 182 406 452 715
Sales and marketing 1,028 1,288 2,001 2,495
General and administrative 763 665 1,534 1,460
Total operating expenses 2,506 2,620 4,937 5,172
Loss from operations (870) (1,317) (1,801) (2,667)
Other expense: (96) (24) (171) (46)
Net loss $ (966) $ (1,341) $ (1,972) $ (2,713)
Net loss per share, basic and diluted $ (0.19) $ (0.27) $ (0.38) $ (0.56)
Weighted average number of shares used in computing basic and diluted loss per share 5,123,568 4,978,878 5,123,568 4,871,614
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current Assets:    
Cash $ 1,022 $ 405
Trade accounts receivable, net of allowance for doubtful accounts of $94 and $183, respectively 607 1,278
Prepaid expenses and other current assets 126 69
Total current assets 1,755 1,752
Assets for lease, net 839 830
Property and equipment, net 452 497
Long-term deposits 15  
Total assets 3,061 3,079
Current liabilities:    
Accounts payable 430 839
Accrued expenses 2,183 2,317
Deferred revenue 667 952
Total current liabilities 3,280 4,108
Long-term liabilities:    
Deferred rent 43 43
Accrued interest expense 85  
Related party loan payable net of debt discount of $199 and $0, respectively 1,301  
Loan payable net of debt discount of $95 and $0, respectively 883  
Total long-term liabilities 2,312 43
Stockholders' deficit:    
Common stock, $0.001 par value; 50,000,000 shares authorized; 5,148,568 and 5,148,568 shares issued, and 5,123,568 and 5,123,568 outstanding (net of treasury shares of 25,000 and 25,000), respectively 5 5
Additional paid-in capital 21,804 21,291
Accumulated deficit (24,340) (22,368)
Total stockholders' deficit (2,531) (1,072)
Total liabilities and stockholders' deficit $ 3,061 $ 3,079
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Balance Sheets (Unaudited) (Parentheticals) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts on trade accounts receivable (in dollars) $ 94 $ 183
Debt discount on related party loan payable 199  
Loan net of debt discount (in dollars) $ 95 $ 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 5,148,568 5,148,568
Common stock, shares outstanding 5,123,568 5,123,568
Treasury stock, shares 25,000 25,000
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (1,972) $ (2,713)
Reconciliation of Net Loss to Net Cash Used in Operating Activities:    
Amortization of debt discount 84 37
Depreciation 221 129
Loss on disposal of assets for lease 136 44
Allowance for doubtful accounts 18 73
Stock-based compensation expense 135 63
Changes in Operating Assets and Liabilities:    
Trade accounts receivable 653 20
Prepaid expenses and other current assets (72) 9
Accounts payable (409) 27
Accrued expenses (49) 21
Deferred revenue (285) (132)
Net Cash Used in Operating Activities (1,540) (2,422)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Additions to property and equipment (15) (45)
Purchase of assets for lease (306) (261)
Net Cash Used in Investing Activities (321) (306)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Issuance of common stock   999
Stock options exercised   13
Offering costs   (100)
Proceeds from loans payable 2,478  
Net Cash Provided by Financing Activities 2,478 912
INCREASE (DECREASE) IN CASH 617 (1,816)
CASH, BEGINNING OF PERIOD 405 4,156
CASH, END OF PERIOD 1,022 2,340
Cash paid for interest   $ 13
Supplemental disclosure of noncash financing activity:    
Fair value of warrants issued to lenders $ 363  
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation
1. Basis of Presentation

 

Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K filed with the SEC on February 26, 2016 (the “Annual Report”). The balance sheet as of December 31, 2015 included in this report has been derived from the audited financial statements included in the Annual Report. In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year. Items in prior period financial statements have been adjusted to conform with the current period presentation.
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Going Concern
 6 Months Ended
Jun. 30, 2016
Going Concern [Abstract]  
Going Concern
2. Going Concern

 

The Company has incurred recurring losses since inception and expects to continue to incur losses as a result of costs and expenses related to the Company’s marketing and other promotional activities, research and continued development of its product. As of June 30, 2016, the Company has negative working capital of $1,525, cash of $1,022 and stockholders’ deficit of $2,531. The Company’s principal sources of cash have included the issuance of equity securities, borrowings under loan agreements, revenue from leasing its product and providing testing services. To increase revenue, the Company’s operating expenses will continue to grow and, as a result, the Company will need to generate significant additional revenue to achieve profitability.

 

The Company’s financial statements as of and for the three and six months ended June 30, 2016 have been prepared under the assumption that the Company will continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate additional revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company can give no assurances that additional capital that the Company is able to obtain, if any, will be sufficient to meet the Company’s needs. If the Company is unable to raise additional capital or increase revenue from leasing its product and providing testing services within the next twelve months to continue to fund operations at its current cash expenditure levels, the Company’s operations will need to be curtailed. The foregoing conditions raise substantial doubt about the Company’s ability to continue as a going concern.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Assets for Lease, net
 6 Months Ended
Jun. 30, 2016
Leases, Capital [Abstract]  
Assets for Lease, net
3. Assets for Lease, net

 

Assets for lease consist of the following:

 

    June 30, 
2016		     December 31, 
2015		  
             
Assets for lease   $ 1,333     $ 1,280  
Less: Accumulated Depreciation     (494 )     (450 )
Assets for lease, net   $ 839     $ 830  

 

Depreciation expense amounted to $81 and $66 for the three months ended June 30, 2016 and June 30, 2015, respectively. Depreciation expense amounted to $161 and $123 for the six months ended June 30, 2016 and June 30, 2015, respectively. Reduction to accumulated depreciation for returned items was $88 and $27 for the three months ended June 30, 2016 and June 30, 2015, respectively. Reduction to accumulated depreciation for returned items was $117 and $41 for the six months ended June 30, 2016 and June 30, 2015, respectively.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment, net
 6 Months Ended
Jun. 30, 2016
Property, Plant and Equipment [Abstract]  
Property and Equipment, net
4. Property and Equipment, net

 

Property and equipment, net consists of the following:

 

    June 30, 
2016		     December 31, 
2015		  
             
Property and equipment   $ 557     $ 542  
Less: accumulated depreciation     (105 )     (45 )
Property and equipment, net   $ 452     $ 497  

 

Depreciation expense amounted to $30 and $4 for the three months ended June 30, 2016 and 2015, respectively. Depreciation expense amounted to $60 and $6 for the six months ended June 30, 2016 and 2015, respectively.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accrued Expenses
 6 Months Ended
Jun. 30, 2016
Accrued Liabilities, Current [Abstract]  
Accrued Expenses
5. Accrued Expenses

 

Accrued expenses consist of the following:

 

    June 30, 
2016		     December 31, 
2015		  
             
Offering Costs   $ 227     $ 227  
Compensation     1,436       1,093  
Miscellaneous Accruals     520       997  
Total Accrued Expenses   $ 2,183     $ 2,317  

 

The accumulated offering costs that were accrued pertain to consulting fees associated with securing equity financing for the Company prior to the initial public offering. Prior to becoming Chief Executive Officer (“CEO”), the Company’s current CEO performed consulting services for the Company, which included managing finance, sales, marketing, operational and strategic planning for the Company, as well as assistance and strategic guidance in securing financing. The Company has agreed to a payment date of December 31, 2016 for these fees.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
6. Commitments and Contingencies

 

Facilities Leases

 

Facilities lease expense recognized by the Company was $22 and $65 for the three months ended June 30, 2016 and 2015, respectively. Facilities lease expense recognized by the Company was $37 and $101 for the six months ended June 30, 2016 and 2015, respectively.

 

On September 23, 2014, the Company entered into a 36-month lease agreement for office space for the sales and marketing team located in Menlo Park, CA. The lease term commenced February 1, 2015 and is effective through January 31, 2018. Payments required under the terms of the lease are $17.0 per month from February 2015 to January 2016, $17.5 per month from February 2016 to January 2017, and $18.0 per month from February 2017 to January 2018. The Company anticipates total future lease payments of $104.8 for the year ended December 31, 2016; $215.4 for the year ended December 31, 2017; and $18.0 for the year ended December 31, 2018. On July 15, 2015, the Company entered into a 30-month sublease agreement for the Menlo Park office space, which commenced August 1, 2015 and is effective through the term of the lease, January 31, 2018. Payments required to the Company under the terms of the sublease are $15.5 per month from August 2015 to July 2016,

 

$16.0 per month from August 2016 to July 2017, and $16.5 per month from August 2017 to January 2018. The Company anticipates receipt of total future sublease payments of $95.5 for the year ended December 31, 2016; $194.4 for the year ended December 31, 2017; and $16.5 for the year ended December 31, 2018.

 

Loans Payable

 

Loans from Related Parties 

 

On January 15, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $1,000 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $1,000 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

On January 21, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $500 unsecured loan for a 24-month term at a fixed interest rate of 5% p.a. Under the loan agreement, the Company will pay $500 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

Other Loans

 

On March 31, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $700 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $700 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 79,459 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

On April 5, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $160 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $160 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 18,162 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

On May 20, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $80 unsecured loan for a 24-month term at a fixed interest rate of 10% p.a. Under the loan agreement, the Company will pay $80 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the

  

Company issued the accredited investor a two-year warrant to purchase 9,081 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

 

The Company uses the Black-Scholes pricing model to determine the relative fair market value of warrants. The relative fair market value of each warrant is estimated on the date of grant. The relative fair value of the warrants granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented:

 

    Three months ended
June 30,		     Six months ended June 30,  
    2016     2015     2016     2015  
Expected term (in years)     2       -       2       -  
Risk-free interest rate     0.73 – 0.89 %     -       0.73 – 0.89 %     -  
Expected volatility     98.1 – 99.0 %     -       97.7 – 99.0 %     -  
Expected dividend rate.     0 %     -       0 %     -  

 

The assumptions are based on the following for each of the years presented:

 

Valuation Method — The Company estimates the relative fair value of warrants using the Black-Scholes pricing model.

 

Expected Term — The Company uses the amount of time the warrants are exercisable per the contractual terms of the award.

 

Volatility — Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the warrants.

 

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the warrants.

 

Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

 

For the three months ended June 30, 2016 and 2015 interest expense was $96 and $25, respectively. Of this total interest expense, the portion related to amortization of debt discount was $48 and $19, respectively. For the six months ended June 30, 2016 and 2015 interest expense was $170 and $49, respectively. Of this total interest expense, the portion related to amortization of debt discount was $84 and $37, respectively.

 

Indemnification Obligations

 

The Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company’s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company’s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment

 under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Loss Per Common Share
 6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Net Loss Per Common Share
7. Net Loss Per Common Share

 

Because the Company was in a loss position for each of the periods presented, diluted net loss per share is the same as basic net loss per share for each period as the inclusion of all potential common shares outstanding would have been anti-dilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive:

 

    Three months ended
June 30,		     Six months ended
June 30,		  
    2016     2015     2016     2015  
Weighted average shares outstanding:                                
Common stock warrants     706,331       359,714       645,353       359,714  
Options     2,069,911       736,722       2,027,480       727,069  
Total     2,776,242       1,096,436       2,672,833       1,086,783  
 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Option Plan
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Option Plan
8. Stock Option Plan

 

The Company’s stock-based compensation program is designed to attract and retain employees while also aligning employees' interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (“2007 Plan”) or the stockholder-approved 2014 Stock Incentive Plan (“2014 Plan”). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the “Share Reserve”), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company’s Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. On January 1, 2015, the Share Reserve increased by 188,640 shares due to the automatic 4% increase. On January 1, 2016, the Share Reserve increased by 204,943 shares due to the automatic 4% increase. The Share Reserve is currently 2,343,583 shares for the year ending December 31, 2016.

 

In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of June 30, 2016, 0 shares of an aggregate total of 407,500 shares were available for future stock-based compensation grants under the 2007 Plan and 666,121 shares of an aggregate total of 2,343,583 shares were available for future stock-based compensation grants under the 2014 Plan.

 

Aggregate intrinsic value represents the difference between the closing market value as of June 30, 2016 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company’s stock option activity and related information for the six months ended June 30, 2016 is as follows:

 

    Options Outstanding  
    Number of
Stock Options
Outstanding		     Weighted
Average
Exercise Price		     Weighted
Average
Remaining
Contractual
Term (In Years)		     Aggregate
Intrinsic Value
 (in thousands)		  
Balance, January 1, 2016     1,909,911     $ 2.58       8.56     $ 813  
Options granted     160,000       2.23                  
Options exercised     -       -                  
Options forfeited/canceled     394       3.44                  
Balance, June 30, 2016     2,069,517     $ 2.58       8.18     $ 280  
Exercisable as of June 30, 2016     1,581,140     $ 2.61       7.92     $ 280  

 

The total compensation cost related to unvested stock option awards not yet recognized was $802 as of June 30, 2016. The weighted average period over which the total unrecognized compensation cost related to these unvested stock awards will be recognized is 2.77 years. The estimated fair value of option shares vested during the quarters ended June 30, 2016 and 2015 was $66 and $31, respectively. The estimated fair value of option shares vested during the six months ended June 30, 2016 and 2015 was $135 and $63, respectively. The weighted average fair value of options granted during the quarter ended June 30, 2015 was $2.32 per share, or an aggregate grant date fair value of $116, respectively. There were no options granted during the quarter ended June 30, 2016. The weighted average fair value of options granted during the six months ended June 30, 2016 and 2015 was $1.43 per share and $1.75 per share, respectively, or an aggregate grant date fair value of $229 and $219, respectively.

 

On February 18, 2016 the Compensation Committee of the Company’s Board of Directors granted, and the full Board ratified, an option to acquire an aggregate of 125,000 shares under the 2014 Plan to the Company’s CEO. This option vests 25% on the one-year anniversary of the grant date and monthly thereafter for 36 months, such that the option is vested in full on the four-year anniversary of the grant date. On February 18, 2016 the Company’s Compensation Committee granted, and the full Board ratified, options to each of the then-seated non-employee Directors to acquire 5,000 shares, for an aggregate of 35,000 shares, under the 2014 Plan. These options vest on the one-year anniversary of their grant date.

 

Determining the Fair Value of Stock Options

 

The Company uses the Black-Scholes pricing model to determine the fair value of stock options. The fair value of each option grant is estimated on the date of the grant. The following assumptions for the periods presented were:

 

    Three months ended
June 30,		     Six months ended June 30,  
    2016     2015     2016     2015  
Expected term (in years)     -       5       5       5  
Risk-free interest rate     -       1.6 %     1.21 %     1.5 – 1.6 %
Expected volatility     -       82.5 %     80.4 %     82.5 – 83.3 %
Expected dividend rate.     -       0 %     0 %     0 %

 

The assumptions are based on the following for each of the years presented:

 

Valuation Method — The Company estimates the fair value of its stock options using the Black-Scholes option pricing model.

 

Expected Term — The Company estimates the expected term consistent with the simplified method identified by the SEC. The Company elected to use the simplified method because of its limited history of stock option exercise activity and its stock options meet the criteria of the “plain-vanilla” options as defined by the SEC. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award.

 Volatility — Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the options.

 

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options.

 

Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

 

Forfeiture — The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of the awards, which are generally the vesting periods. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.

 

The Company has recorded an expense of $66 and $31 as it relates to stock-based compensation for the three months ended June 30, 2016 and 2015, respectively. The Company has recorded an expense of $135 and $63 as it relates to stock-based compensation for the six months ended June 30, 2016 and 2015, respectively, which was allocated as follows based on the role and responsibility of the recipient in the Company:

 

    Three months ended June 30,     Six months ended June 30  
    2016     2015     2016     2015  
Cost of Revenue   $ 1     $ 1     $ 1     $ 1  
Engineering and Product Development     5       5       18       7  
Sales and Marketing     17       10       42       25  
General and Administrative     43       15       74       30  
Total   $ 66     $ 31     $ 135     $ 63  
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Subsequent Events
 6 Months Ended
Jun. 30, 2016
Subsequent Events [Abstract]  
Subsequent Events
9. Subsequent Events

 

None.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies and Estimates (Policies)
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

 

Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K filed with the SEC on February 26, 2016 (the “Annual Report”). The balance sheet as of December 31, 2015 included in this report has been derived from the audited financial statements included in the Annual Report. In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year. Items in prior period financial statements have been adjusted to conform with the current period presentation.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Assets for lease, net (Tables)
 6 Months Ended
Jun. 30, 2016
Leases, Capital [Abstract]  
Schedule of assets for lease
    June 30, 
2016		     December 31, 
2015		  
             
Assets for lease   $ 1,333     $ 1,280  
Less: Accumulated Depreciation     (494 )     (450 )
Assets for lease, net   $ 839     $ 830  
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment, net (Tables)
 6 Months Ended
Jun. 30, 2016
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
    June 30, 
2016		     December 31, 
2015		  
             
Property and equipment   $ 557     $ 542  
Less: accumulated depreciation     (105 )     (45 )
Property and equipment, net   $ 452     $ 497  
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accrued Expenses (Tables)
 6 Months Ended
Jun. 30, 2016
Accrued Liabilities, Current [Abstract]  
Schedule of accrued expenses
    June 30, 
2016		     December 31, 
2015		  
             
Offering Costs   $ 227     $ 227  
Compensation     1,436       1,093  
Miscellaneous Accruals     520       997  
Total Accrued Expenses   $ 2,183     $ 2,317  
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Tables)
 6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Schedule of relative fair value of the warrants granted using the Black-Scholes pricing model
    Three months ended
June 30,		     Six months ended June 30,  
    2016     2015     2016     2015  
Expected term (in years)     2       -       2       -  
Risk-free interest rate     0.73 – 0.89 %     -       0.73 – 0.89 %     -  
Expected volatility     98.1 – 99.0 %     -       97.7 – 99.0 %     -  
Expected dividend rate.     0 %     -       0 %     -  
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Loss Per Common Share (Tables)
 6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Schedule of common stock equivalents excluded from the computation of diluted net loss per share
    Three months ended
June 30,		     Six months ended
June 30,		  
    2016     2015     2016     2015  
Weighted average shares outstanding:                                
Common stock warrants     706,331       359,714       645,353       359,714  
Options     2,069,911       736,722       2,027,480       727,069  
Total     2,776,242       1,096,436       2,672,833       1,086,783  
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Option Plan (Tables)
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of summary of stock-based compensation activity

 

    Options Outstanding  
    Number of
Stock Options
Outstanding		     Weighted
Average
Exercise Price		     Weighted
Average
Remaining
Contractual
Term (In Years)		     Aggregate
Intrinsic Value
 (in thousands)		  
Balance, January 1, 2016     1,909,911     $ 2.58       8.56     $ 813  
Options granted     160,000       2.23                  
Options exercised     -       -                  
Options forfeited/canceled     394       3.44                  
Balance, June 30, 2016     2,069,517     $ 2.58       8.18     $ 280  
Exercisable as of June 30, 2016     1,581,140     $ 2.61       7.92     $ 280  
Schedule of weighted-average Black-Scholes fair value assumptions
    Three months ended
June 30,		     Six months ended June 30,  
    2016     2015     2016     2015  
Expected term (in years)     -       5       5       5  
Risk-free interest rate     -       1.6 %     1.21 %     1.5 – 1.6 %
Expected volatility     -       82.5 %     80.4 %     82.5 – 83.3 %
Expected dividend rate.     -       0 %     0 %     0 %
 
Schedule of stock-based compensation based on the role and responsibility of the recipient in the Company
    Three months ended June 30,     Six months ended June 30  
    2016     2015     2016     2015  
Cost of Revenue   $ 1     $ 1     $ 1     $ 1  
Engineering and Product Development     5       5       18       7  
Sales and Marketing     17       10       42       25  
General and Administrative     43       15       74       30  
Total   $ 66     $ 31     $ 135     $ 63  

 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Going Concern (Detail Textuals) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Jun. 30, 2015
Dec. 31, 2014
Going Concern [Abstract]        
Working capital $ (1,525)      
Cash 1,022 $ 405 $ 2,340 $ 4,156
Stockholders' deficit $ (2,531) $ (1,072)    
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Assets for Lease, net - Summary of assets for lease (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Leases, Capital [Abstract]    
Assets for lease $ 1,333 $ 1,280
Less: Accumulated Depreciation (494) (450)
Assets for lease, net $ 839 $ 830
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Assets for Lease, net (Detail Textuals) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Leases, Capital [Abstract]        
Depreciation expense $ 81 $ 66 $ 161 $ 123
Reduction to accumulated depreciation for returned items $ 88 $ 27 $ 117 $ 41
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment, net (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Property, Plant and Equipment [Abstract]    
Property and equipment $ 557 $ 542
Less: accumulated depreciation (105) (45)
Property and equipment, net $ 452 $ 497
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment, net (Detail Textuals) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 30 $ 4 $ 60 $ 6
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accrued Expenses - Summary of accrued expenses (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Accrued Liabilities, Current [Abstract]    
Offering Costs $ 227 $ 227
Compensation 1,436 1,093
Miscellaneous Accruals 520 997
Total Accrued Expenses $ 2,183 $ 2,317
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]        
Expected term (in years) 2 years   2 years  
Risk-free interest rate    
Expected volatility    
Expected dividend rate 0.00% 0.00%
Minimum        
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]        
Risk-free interest rate 0.73%   0.73%  
Expected volatility 98.10%   97.70%  
Maximum        
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]        
Risk-free interest rate 0.89%   0.89%  
Expected volatility 99.00%   99.00%  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Detail Textuals) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 15, 2015
Sep. 23, 2014
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Property Subject to or Available for Operating Lease [Line Items]            
Facilities lease expense     $ 22,000 $ 65,000 $ 37,000 $ 101,000
Lease Agreement            
Property Subject to or Available for Operating Lease [Line Items]            
Term specified for lease agreement   36 months        
Future lease payments for December 31, 2016     104,800   104,800  
Future lease payments for December 31, 2017     215,400   215,400  
Future lease payments for December 31, 2018     18,000   18,000  
Lease Agreement | Lease term from February 2015 to January 2016            
Property Subject to or Available for Operating Lease [Line Items]            
Payments required per month under terms of lease agreement         17,000  
Lease Agreement | Lease term from February 2016 to January 2017            
Property Subject to or Available for Operating Lease [Line Items]            
Payments required per month under terms of lease agreement         17,500  
Lease Agreement | Lease term from February 2017 to January 2018            
Property Subject to or Available for Operating Lease [Line Items]            
Payments required per month under terms of lease agreement         18,000  
Sub Lease Agreement            
Property Subject to or Available for Operating Lease [Line Items]            
Term specified for lease agreement 30 months          
Future lease payments for December 31, 2016     95,500   95,500  
Future lease payments for December 31, 2017     194,400   194,400  
Future lease payments for December 31, 2018     $ 16,500   16,500  
Sub Lease Agreement | Lease term from August 2015 to July 2016            
Property Subject to or Available for Operating Lease [Line Items]            
Payments required per month under terms of lease agreement         15,500  
Sub Lease Agreement | Lease term from August 2016 to July 2017            
Property Subject to or Available for Operating Lease [Line Items]            
Payments required per month under terms of lease agreement         16,000  
Sub Lease Agreement | Lease term from August 2017 to July 2018            
Property Subject to or Available for Operating Lease [Line Items]            
Payments required per month under terms of lease agreement         $ 16,500  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Detail Textuals 1) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 05, 2016
Jan. 15, 2016
May 20, 2016
Mar. 31, 2016
Jan. 21, 2016
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Commitments And Contingencies [Line Items]                  
Interest expense           $ 96 $ 25 $ 170 $ 49
Amortization of debt discount           $ 48 $ 19 $ 84 $ 37
Unsecured Debt | Fixed rate of interest 10%                  
Commitments And Contingencies [Line Items]                  
Unsecured loan   $ 1,000              
Term of secured loan   24 months              
Unsecured loan rate of interest   10.00%              
Unsecured loan principal and interest payment   $ 1,000              
Additional indebtedness limit   $ 50              
Term of warrant   2 years              
Number of warrant issued to purchase common stock   114,286              
Exercise price per warrants   $ 1.75              
Minimum percentage holding required by holder to retain exercising rights   more than 19.99%              
Unsecured Debt | Fixed rate of interest 10% | Accredited investor                  
Commitments And Contingencies [Line Items]                  
Unsecured loan $ 160   $ 80 $ 700          
Term of secured loan 24 months   24 months 24 months          
Unsecured loan rate of interest 10.00%   10.00% 10.00%          
Unsecured loan principal and interest payment $ 160   $ 80 $ 700          
Term of warrant 2 years   2 years 2 years          
Number of warrant issued to purchase common stock 18,162   9,081 79,459          
Exercise price per warrants $ 1.85   $ 1.85 $ 1.85          
Minimum percentage holding required by holder to retain exercising rights more than 4.99%   more than 4.99% more than 4.99%          
Unsecured Debt | Fixed rate of interest 5%                  
Commitments And Contingencies [Line Items]                  
Unsecured loan         $ 500        
Term of secured loan         24 months        
Unsecured loan rate of interest         5.00%        
Unsecured loan principal and interest payment         $ 500        
Additional indebtedness limit         $ 50        
Term of warrant         2 years        
Number of warrant issued to purchase common stock         114,286        
Exercise price per warrants         $ 1.75        
Minimum percentage holding required by holder to retain exercising rights         more than 19.99%        
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Loss Per Common Share (Details) - shares
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Weighted average shares outstanding:        
Total 2,776,242 1,096,436 2,672,833 1,086,783
Common stock warrants        
Weighted average shares outstanding:        
Total 706,331 359,714 645,353 359,714
Options        
Weighted average shares outstanding:        
Total 2,069,911 736,722 2,027,480 727,069
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Option Plan - Summary of stock-based compensation activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Number of Stock Options Outstanding    
Balance, January 1, 2016 1,909,911  
Options granted 160,000  
Options exercised  
Options forfeited/canceled 394  
Balance, June 30, 2016 2,069,517 1,909,911
Exercisable as of June 30, 2016 1,581,140  
Weighted Average Exercise Price    
Balance, January 1, 2016 $ 2.58  
Options granted 2.23  
Options exercised  
Options forfeited/canceled 3.44  
Balance, June 30, 2016 2.58 $ 2.58
Exercisable as of June 30, 2016 $ 2.61  
Weighted Average Remaining Contractual Term, Options Outstanding (in years) 8 years 2 months 5 days 8 years 6 months 22 days
Weighted Average Remaining Contractual Term, Options Exercisable (in years) 7 years 11 months 1 day  
Aggregate Intrinsic Value, Options Outstanding $ 280 $ 813
Aggregate Intrinsic Value, Options Exercisable $ 280  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Option Plan - Weighted-average Black-Scholes fair value assumptions (Details 1)
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected term (in years)   5 years 5 years 5 years
Risk free interest rate 1.60% 1.21%  
Expected volatility 82.50% 80.40%  
Expected dividend rate 0.00% 0.00% 0.00%
Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Risk free interest rate       1.50%
Expected volatility       82.50%
Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Risk free interest rate       1.60%
Expected volatility       83.30%
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Option Plan - Stock-based compensation (Details 2) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 66 $ 31 $ 135 $ 63
Cost of Revenue        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 1 1 1 1
Engineering and Product Development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 5 5 18 7
Sales and Marketing        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 17 10 42 25
General and Administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 43 $ 15 $ 74 $ 30
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Option Plan (Detail Textuals) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2016
Oct. 31, 2015
Jan. 31, 2015
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Total unrecognized compensation cost related to non-vested awards       $ 802   $ 802  
Weighted average period of unvested stock awards           2 years 9 months 7 days  
Total estimated grant date fair value of options vested       $ 66 $ 31 $ 135 $ 63
Weighted average grant date fair value of options granted         $ 2.32 $ 1.43 $ 1.75
Aggregate grant date fair value         $ 116 $ 229 $ 219
2007 Key Person Stock Option Plan | Stock options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of shares available for future stock-based compensation grants       0   0  
Aggregate number of share reserve       407,500   407,500  
2014 Stock Incentive Plan | Stock options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of shares available for future stock-based compensation grants       666,121   666,121  
Aggregate number of share reserve       450,000   450,000  
Maximum term of stock option grants   10 years          
Percentage of shares reserve increased 4.00% 4.00% 4.00%        
Number of share reserve increased 204,943 1,500,000 188,640     2,343,583  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock Option Plan (Detail Textuals 1) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 18, 2016
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of stock option granted       160,000  
Stock-based compensation expense   $ 66 $ 31 $ 135 $ 63
2014 Stock Incentive Plan | Stock options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Aggregate number of share reserve   450,000   450,000  
2014 Stock Incentive Plan | Stock options | Board of Directors          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Aggregate number of share reserve 125,000        
Percentage of options vested and exercisable 25.00%        
2014 Stock Incentive Plan | Stock options | Board of Directors | Vesting period, Tranche one          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period of option 1 year        
2014 Stock Incentive Plan | Stock options | Board of Directors | Vesting period, tranche two          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period of option 36 months        
2014 Stock Incentive Plan | Stock options | Board of Directors | Vesting period, tranche three          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period of option 4 years        
2014 Stock Incentive Plan | Stock options | Non Employee Director          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Aggregate number of share reserve 35,000        
Number of stock option granted 5,000        
EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 73 156 1 false 28 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://semlerscientific.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://semlerscientific.com/role/CondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 2 false false R3.htm 003 - Statement - Condensed Balance Sheets Sheet http://semlerscientific.com/role/CondensedBalanceSheetsUnaudited Condensed Balance Sheets Statements 3 false false R4.htm 004 - Statement - Condensed Balance Sheets (Unaudited) (Parentheticals) Sheet http://semlerscientific.com/role/CondensedBalanceSheetsUnauditedParentheticals Condensed Balance Sheets (Unaudited) (Parentheticals) Statements 4 false false R5.htm 005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://semlerscientific.com/role/CondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - Basis of Presentation Sheet http://semlerscientific.com/role/BasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 007 - Disclosure - Going Concern Sheet http://semlerscientific.com/role/GoingConcern Going Concern Notes 7 false false R8.htm 008 - Disclosure - Assets for Lease, net Sheet http://semlerscientific.com/role/AssetsForLeaseNet Assets for Lease, net Notes 8 false false R9.htm 009 - Disclosure - Property and Equipment, net Sheet http://semlerscientific.com/role/PropertyAndEquipmentNet Property and Equipment, net Notes 9 false false R10.htm 010 - Disclosure - Accrued Expenses Sheet http://semlerscientific.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 011 - Disclosure - Commitments and Contingencies Sheet http://semlerscientific.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 012 - Disclosure - Net Loss Per Common Share Sheet http://semlerscientific.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 12 false false R13.htm 013 - Disclosure - Stock Option Plan Sheet http://semlerscientific.com/role/StockOptionPlan Stock Option Plan Notes 13 false false R14.htm 014 - Disclosure - Subsequent Events Sheet http://semlerscientific.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 015 - Disclosure - Summary of Significant Accounting Policies and Estimates (Policies) Sheet http://semlerscientific.com/role/SummaryofSignificantAccountingPoliciesandEstimatesPolicies Summary of Significant Accounting Policies and Estimates (Policies) Policies 15 false false R16.htm 016 - Disclosure - Assets for lease, net (Tables) Sheet http://semlerscientific.com/role/AssetsForLeaseNetTables Assets for lease, net (Tables) Tables 16 false false R17.htm 017 - Disclosure - Property and Equipment, net (Tables) Sheet http://semlerscientific.com/role/PropertyAndEquipmentNetTables Property and Equipment, net (Tables) Tables http://semlerscientific.com/role/PropertyAndEquipmentNet 17 false false R18.htm 018 - Disclosure - Accrued Expenses (Tables) Sheet http://semlerscientific.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://semlerscientific.com/role/AccruedExpenses 18 false false R19.htm 019 - Disclosure - Commitments and Contingencies (Tables) Sheet http://semlerscientific.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://semlerscientific.com/role/CommitmentsAndContingencies 19 false false R20.htm 020 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://semlerscientific.com/role/NetLossPerCommonSharetables Net Loss Per Common Share (Tables) Tables http://semlerscientific.com/role/NetLossPerCommonShare 20 false false R21.htm 021 - Disclosure - Stock Option Plan (Tables) Sheet http://semlerscientific.com/role/StockBasedCompensationTables Stock Option Plan (Tables) Tables http://semlerscientific.com/role/StockOptionPlan 21 false false R22.htm 022 - Disclosure - Going Concern (Detail Textuals) Sheet http://semlerscientific.com/role/GoingConcernDetailTextuals Going Concern (Detail Textuals) Details http://semlerscientific.com/role/GoingConcern 22 false false R23.htm 023 - Disclosure - Assets for Lease, net - Summary of assets for lease (Details) Sheet http://semlerscientific.com/role/AssetsForLeaseNetSummaryOfAssetsForLeaseDetails Assets for Lease, net - Summary of assets for lease (Details) Details 23 false false R24.htm 024 - Disclosure - Assets for Lease, net (Detail Textuals) Sheet http://semlerscientific.com/role/AssetsForLeaseNetDetailTextuals Assets for Lease, net (Detail Textuals) Details http://semlerscientific.com/role/AssetsForLeaseNet 24 false false R25.htm 025 - Disclosure - Property and Equipment, net (Details) Sheet http://semlerscientific.com/role/PropertyAndEquipmentNetDetails Property and Equipment, net (Details) Details http://semlerscientific.com/role/PropertyAndEquipmentNetTables 25 false false R26.htm 026 - Disclosure - Property and Equipment, net (Detail Textuals) Sheet http://semlerscientific.com/role/PropertyAndEquipmentNetDetailTextuals Property and Equipment, net (Detail Textuals) Details http://semlerscientific.com/role/PropertyAndEquipmentNetTables 26 false false R27.htm 027 - Disclosure - Accrued Expenses - Summary of accrued expenses (Details) Sheet http://semlerscientific.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails Accrued Expenses - Summary of accrued expenses (Details) Details 27 false false R28.htm 028 - Disclosure - Commitments and Contingencies (Details) Sheet http://semlerscientific.com/role/CommitmentsandContingenciesDetails3 Commitments and Contingencies (Details) Details http://semlerscientific.com/role/CommitmentsandContingenciesTables 28 false false R29.htm 029 - Disclosure - Commitments and Contingencies (Detail Textuals) Sheet http://semlerscientific.com/role/CommitmentsAndContingenciesDetailTextuals Commitments and Contingencies (Detail Textuals) Details http://semlerscientific.com/role/CommitmentsandContingenciesTables 29 false false R30.htm 030 - Disclosure - Commitments and Contingencies (Detail Textuals 1) Sheet http://semlerscientific.com/role/SubsequentEventsDetailTextuals Commitments and Contingencies (Detail Textuals 1) Details http://semlerscientific.com/role/CommitmentsandContingenciesTables 30 false false R31.htm 031 - Disclosure - Net Loss Per Common Share (Details) Sheet http://semlerscientific.com/role/NetLossPerCommonShareDetails Net Loss Per Common Share (Details) Details http://semlerscientific.com/role/NetLossPerCommonSharetables 31 false false R32.htm 032 - Disclosure - Stock Option Plan - Summary of stock-based compensation activity (Details) Sheet http://semlerscientific.com/role/StockBasedCompensationSummaryOfStockBasedCompensationActivityDetails1 Stock Option Plan - Summary of stock-based compensation activity (Details) Details 32 false false R33.htm 033 - Disclosure - Stock Option Plan - Weighted-average Black-Scholes fair value assumptions (Details 1) Sheet http://semlerscientific.com/role/StockBasedCompensationWeightedAverageBlackScholesFairValueAssumptionsDetails Stock Option Plan - Weighted-average Black-Scholes fair value assumptions (Details 1) Details 33 false false R34.htm 034 - Disclosure - Stock Option Plan - Stock-based compensation (Details 2) Sheet http://semlerscientific.com/role/StockOptionPlanDetails2 Stock Option Plan - Stock-based compensation (Details 2) Details 34 false false R35.htm 035 - Disclosure - Stock Option Plan (Detail Textuals) Sheet http://semlerscientific.com/role/Stockbasedcompensationdetailtextuals Stock Option Plan (Detail Textuals) Details http://semlerscientific.com/role/StockBasedCompensationTables 35 false false R36.htm 036 - Disclosure - Stock Option Plan (Detail Textuals 1) Sheet http://semlerscientific.com/role/StockBasedCompensationDetailTextuals1 Stock Option Plan (Detail Textuals 1) Details http://semlerscientific.com/role/StockBasedCompensationTables 36 false false All Reports Book All Reports smlr-20160630.xml smlr-20160630.xsd smlr-20160630_cal.xml smlr-20160630_def.xml smlr-20160630_lab.xml smlr-20160630_pre.xml true true ZIP 53 0001571049-16-017008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001571049-16-017008-xbrl.zip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end